www.Cancer-Genetics.org
Navigate
  Breast Cancer

Literature Analysis

Mouse over the terms for more detail; many indicate links which you can click for dedicated pages about the topic.

Tag cloud generated 14 January, 2015 using data from PubMed, MeSH and CancerIndex

Mutated Genes and Abnormal Protein Expression (1079)

How to use this data tableClicking on the Gene or Topic will take you to a separate more detailed page. Sort this list by clicking on a column heading e.g. 'Gene' or 'Topic'.

GeneLocationAliasesNotesTopicPapers
BRCA2 13q12.3 FAD, FACD, FAD1, GLM3, BRCC2, FANCD, PNCA2, FANCD1, XRCC11, BROVCA2 -BRCA2 and Breast Cancer
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA2 and Breast Cancer During Pregnancy
-BRCA2 and Outcome in Breast Cancer
3000
BRCA1 17q21 IRIS, PSCP, BRCAI, BRCC1, FANCS, PNCA4, RNF53, BROVCA1, PPP1R53 Germline
-185delAG mutation (c.68_69delAG) in BRCA1
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA1 mutations in Breast Cancer
3000
MKI67 10q26.2 KIA, MIB-, MIB-1, PPP1R105 -MKI67 and Breast Cancer
1744
TP53 17p13.1 P53, BCC7, LFS1, TRP53 -TP53 mutations in Breast Cancer
1449
ERBB2 17q12 NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu Gene Amplification
-HER2 and Breast Cancer
775
MYC 8q24.21 MRTL, MYCC, c-Myc, bHLHe39 -MYC and Breast Cancer
730
CCND1 11q13 BCL1, PRAD1, U21B31, D11S287E -CCND1 and Breast Cancer
598
NODAL 10q22.1 HTX5 -NODAL and Breast Cancer
475
MUC1 1q21 EMA, MCD, PEM, PUM, KL-6, MAM6, MCKD, PEMT, CD227, H23AG, MCKD1, MUC-1, ADMCKD, ADMCKD1, CA 15-3, MUC-1/X, MUC1/ZD, MUC-1/SEC Prognostic
-MUC1 Expression in Breast Cancer
448
CYP19A1 15q21.1 ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX, P-450AROM -CYP19A1 and Breast Cancer
423
PTEN 10q23.3 BZS, DEC, CWS1, GLM2, MHAM, TEP1, MMAC1, PTEN1, 10q23del -PTEN and Breast Cancer
399
AKT1 14q32.32 AKT, PKB, RAC, CWS6, PRKBA, PKB-ALPHA, RAC-ALPHA -AKT1 and Breast Cancer
337
PROC 2q13-q14 PC, APC, PROC1, THPH3, THPH4 -PROC and Breast Cancer
333
AR Xq12 KD, AIS, TFM, DHTR, SBMA, HYSP1, NR3C4, SMAX1, HUMARA -AR and Breast Cancer
294
ABCB1 7q21.12 CLCS, MDR1, P-GP, PGY1, ABC20, CD243, GP170 -ABCB1 and Breast Cancer
290
BIRC5 17q25 API4, EPR-1 -BIRC5 and Breast Cancer
268
SRC 20q12-q13 ASV, SRC1, c-SRC, p60-Src -SRC and Breast Cancer
265
CDKN1A 6p21.2 P21, CIP1, SDI1, WAF1, CAP20, CDKN1, MDA-6, p21CIP1 -CDKN1A and Breast Cancer
258
KITLG 12q22 SF, MGF, SCF, FPH2, KL-1, Kitl, SHEP7 -KITLG and Breast Cancer
254
CTNNB1 3p21 CTNNB, MRD19, armadillo -CTNNB1 and Breast Cancer
246
CHEK2 22q12.1 CDS1, CHK2, LFS2, RAD53, hCds1, HuCds1, PP1425 -CHEK2 and Breast Cancer
239
PTGS2 1q25.2-q25.3 COX2, COX-2, PHS-2, PGG/HS, PGHS-2, hCox-2, GRIPGHS -PTGS2 (COX2) and Breast Cancer
-COX2 Inhibitors for Breast Cancer
150
CDKN2A 9p21 ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P14ARF, P19ARF, P16INK4, P16INK4A, P16-INK4A -CDKN2A and Breast Cancer
231
ESR1 6q25.1 ER, ESR, Era, ESRA, ESTRR, NR3A1 -ESR1 and Breast Cancer
228
TNF 6p21.3 DIF, TNFA, TNFSF2, TNF-alpha -TNF and Breast Cancer
226
CD44 11p13 IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1, CDW44, CSPG8, HCELL, HUTCH-I, ECMR-III -CD44 and Breast Cancer
224
ATM 11q22-q23 AT1, ATA, ATC, ATD, ATE, ATDC, TEL1, TELO1 -ATM and Breast Cancer
216
BAX 19q13.3-q13.4 BCL2L4 -BAX and Breast Cancer
210
TOP1 20q12-q13.1 TOPI -TOP1 and Breast Cancer
204
MET 7q31 HGFR, AUTS9, RCCP2, c-Met -C-MET and Triple Negative Breast Cancer
-C-MET and Breast Cancer
-Proto-Oncogene Proteins c-met and Triple Negative Breast Cancer
182
CYP2D6 22q13.1 CPD6, CYP2D, CYP2DL1, CYPIID6, P450C2D, P450DB1, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, P450-DB1 -CYP2D6 and Breast Cancer
192
RAD51 15q15.1 RECA, BRCC5, MRMV2, HRAD51, RAD51A, HsRad51, HsT16930 -RAD51 and Breast Cancer
191
PIK3CA 3q26.3 MCM, CWS5, MCAP, PI3K, CLOVE, MCMTC, p110-alpha -PIK3CA and Breast Cancer
180
GSTP1 11q13 PI, DFN7, GST3, GSTP, FAEES3, HEL-S-22 -GSTP1 and Breast Cancer
179
MTOR 1p36.2 FRAP, FRAP1, FRAP2, RAFT1, RAPT1 -MTOR and Breast Cancer
173
KLK3 19q13.41 APS, PSA, hK3, KLK2A1 -PSA expression in Breast Cancer
166
CYP1A1 15q24.1 AHH, AHRR, CP11, CYP1, P1-450, P450-C, P450DX -CYP1A1 and Breast Cancer
165
MDM2 12q14.3-q15 HDMX, hdm2, ACTFS -MDM2 and Breast Cancer
164
CDH1 16q22.1 UVO, CDHE, ECAD, LCAM, Arc-1, CD324 -CDH1 and Breast Cancer
159
FGFR2 10q26 BEK, JWS, BBDS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM -FGFR2 and Breast Cancer
157
CDKN1B 12p13.1-p12 KIP1, MEN4, CDKN4, MEN1B, P27KIP1 Prognostic
-CDKN1B and Breast Cancer
151
PPARG 3p25 GLM1, CIMT1, NR1C3, PPARG1, PPARG2, PPARgamma -PPARG and Breast Cancer
147
TIMP1 Xp11.3-p11.23 EPA, EPO, HCI, CLGI, TIMP -TIMP1 and Breast Cancer
144
HIF1A 14q23.2 HIF1, MOP1, PASD8, HIF-1A, bHLHe78, HIF-1alpha, HIF1-ALPHA -HIF1A and Breast Cancer
141
FOS 14q24.3 p55, AP-1, C-FOS -FOS and Breast Cancer
140
MMP2 16q13-q21 CLG4, MONA, CLG4A, MMP-2, TBE-1, MMP-II -MMP2 and Breast Cancer
139
GSTM1 1p13.3 MU, H-B, GST1, GTH4, GTM1, MU-1, GSTM1-1, GSTM1a-1a, GSTM1b-1b -GSTM1 and Breast Cancer
135
TFF1 21q22.3 pS2, BCEI, HPS2, HP1.A, pNR-2, D21S21 -TFF1 and Breast Cancer
135
BLID 11q24.1 BRCC2 -BLID and Breast Cancer
124
VEGFA 6p12 VPF, VEGF, MVCD1 -VEGFA and Breast Cancer
122
CYP1B1 2p22.2 CP1B, GLC3A, CYPIB1, P4501B1 -CYP1B1 and Breast Cancer
122
STAT3 17q21.31 APRF, HIES, ADMIO -STAT3 and Breast Cancer
122
CD24 6q21 CD24A -CD24 and Breast Cancer
121
BCL2 18q21.3 Bcl-2, PPP1R50 -BCL2 and Breast Cancer
120
CXCR4 2q21 FB22, HM89, LAP3, LCR1, NPYR, WHIM, CD184, LAP-3, LESTR, NPY3R, NPYRL, HSY3RR, NPYY3R, D2S201E -CXCR4 and Breast Cancer
120
TGFB1 19q13.1 CED, LAP, DPD1, TGFB, TGFbeta -TGFB1 and Breast Cancer
118
IGF1R 15q26.3 IGFR, CD221, IGFIR, JTK13 -IGF1R and Breast Cancer
115
COMT 22q11.21 HEL-S-98n -COMT and Breast Cancer
115
CAMP 3p21.3 LL37, CAP18, CRAMP, HSD26, CAP-18, FALL39, FALL-39 -CAMP and Breast Cancer
114
CASP8 2q33-q34 CAP4, MACH, MCH5, FLICE, ALPS2B, Casp-8 -CASP8 and Breast Cancer
110
CISH 3p21.3 CIS, G18, SOCS, CIS-1, BACTS2 -CISH and Breast Cancer
108
XRCC1 19q13.2 RCC -XRCC1 and Breast Cancer
105
FLCN 17p11.2 BHD, FLCL -FLCN and Breast Cancer
105
TOP2A 17q21-q22 TOP2, TP2A -TOP2A and Breast Cancer
103
PCNA 20pter-p12 ATLD2 -PCNA and Breast Cancer
102
PARP1 1q41-q42 PARP, PPOL, ADPRT, ARTD1, ADPRT1, PARP-1, ADPRT 1, pADPRT-1 -PARP1 and Breast Cancer
99
NOTCH1 9q34.3 hN1, AOS5, TAN1, AOVD1 -NOTCH1 and Breast Cancer
95
GSTT1 22q11.23 -GSTT1 Polymorphisms and Breast Cancer
94
TUBE1 6q21 TUBE, dJ142L7.2 -TUBE1 and Breast Cancer
92
CYP17A1 10q24.3 CPT7, CYP17, S17AH, P450C17 -CYP17A1 and Breast Cancer
90
RASSF1 3p21.3 123F2, RDA32, NORE2A, RASSF1A, REH3P21 -RASSF1 and Breast Cancer
86
TGFBR1 9q22 AAT5, ALK5, ESS1, LDS1, MSSE, SKR4, ALK-5, LDS1A, LDS2A, TGFR-1, ACVRLK4, tbetaR-I -TGFBR1 and Breast Cancer
83
ABCG2 4q22 MRX, MXR, ABCP, BCRP, BMDP, MXR1, ABC15, BCRP1, CD338, GOUT1, CDw338, UAQTL1, EST157481 -ABCG2 and Breast Cancer
83
CDK2 12q13 CDKN2, p33(CDK2) -CDK2 and Breast Cancer
82
BARD1 2q34-q35 -BARD1 and Breast Cancer
80
CXCL12 10q11.1 IRH, PBSF, SDF1, TLSF, TPAR1, SCYB12 -CXCL12 and Breast Cancer
80
E2F1 20q11.2 RBP3, E2F-1, RBAP1, RBBP3 -E2F1 and Breast Cancer
77
BAD 11q13.1 BBC2, BCL2L8 -BAD and Breast Cancer
76
NME1 17q21.3 NB, AWD, NBS, GAAD, NDKA, NM23, NDPKA, NDPK-A, NM23-H1 -NME1 and Breast Cancer
76
ERBB3 12q13 HER3, LCCS2, ErbB-3, c-erbB3, erbB3-S, MDA-BF-1, c-erbB-3, p180-ErbB3, p45-sErbB3, p85-sErbB3 -ERBB3 and Breast Cancer
74
ETS1 11q23.3 p54, ETS-1, EWSR2 -ETS1 and Breast Cancer
73
SMAD3 15q22.33 LDS3, LDS1C, MADH3, JV15-2, HSPC193, HsT17436 -SMAD3 and Breast Cancer
73
SULT1A1 16p12.1 PST, STP, STP1, P-PST, ST1A1, ST1A3, TSPST1, HAST1/HAST2 -SULT1A1 and Breast Cancer
73
CYP3A4 7q21.1 HLP, CP33, CP34, CYP3A, NF-25, CYP3A3, P450C3, CYPIIIA3, CYPIIIA4, P450PCN1 -CYP3A4 and Breast Cancer
72
SERPINE1 7q22.1 PAI, PAI1, PAI-1, PLANH1 -SERPINE1 and Breast Cancer
72
TERT 5p15.33 TP2, TRT, CMM9, EST2, TCS1, hTRT, DKCA2, DKCB4, hEST2, PFBMFT1 -TERT and Breast Cancer
72
FOXA1 14q12-q13 HNF3A, TCF3A -FOXA1 and Breast Cancer
71
CDK4 12q14 CMM3, PSK-J3 -CDK4 and Breast Cancer
71
GATA3 10p15 HDR, HDRS -GATA3 and Breast Cancer
71
JUN 1p32-p31 AP1, AP-1, c-Jun -c-Jun and Breast Cancer
70
RHOC 1p13.1 H9, ARH9, ARHC, RHOH9 -RHOC and Breast Cancer
70
TGFA 2p13 TFGA -TGFA and Breast Cancer
69
RB1 13q14.2 RB, pRb, OSRC, pp110, p105-Rb, PPP1R130 -RB1 mutations in Breast Cancer
69
MIR21 17q23.1 MIRN21, miR-21, miRNA21, hsa-mir-21 -MicroRNA miR-21 and Breast Cancer
68
XRCC3 14q32.3 CMM6 -XRCC3 and Breast Cancer
67
FLT1 13q12 FLT, FLT-1, VEGFR1, VEGFR-1 -FLT1 and Breast Cancer
67
CEACAM5 19q13.1-q13.2 CEA, CD66e -CEACAM5 and Breast Cancer
67
SCGB2A2 11q13 MGB1, UGB2 -SCGB2A2 and Breast Cancer
66
IGFBP3 7p12.3 IBP3, BP-53 -IGFBP3 and Breast Cancer
65
BCL2L1 20q11.21 BCLX, BCL2L, BCLXL, BCLXS, Bcl-X, bcl-xL, bcl-xS, PPP1R52, BCL-XL/S -BCL2L1 and Breast Cancer
65
TWIST1 7p21.2 CRS, CSO, SCS, ACS3, CRS1, BPES2, BPES3, TWIST, bHLHa38 -TWIST1 and Breast Cancer
64
PDLIM4 5q31.1 RIL -PDLIM4 and Breast Cancer
63
HRAS 11p15.5 CTLO, HAMSV, HRAS1, RASH1, p21ras, C-H-RAS, H-RASIDX, C-BAS/HAS, C-HA-RAS1 -HRAS and Breast Cancer
63
CCNB1 5q12 CCNB -CCNB1 and Breast Cancer
63
AKT2 19q13.1-q13.2 PKBB, PRKBB, HIHGHH, PKBBETA, RAC-BETA -AKT2 and Breast Cancer
62
FGF2 4q26 BFGF, FGFB, FGF-2, HBGF-2 -FGF2 and Breast Cancer
62
NAT2 8p22 AAC2, PNAT, NAT-2 -NAT2 and Breast Cancer
61
FGF3 11q13 INT2, HBGF-3 -FGF3 and Breast Cancer
61
BRAP 12q24 IMP, BRAP2, RNF52 -BRAP and Breast Cancer
58
MYB 6q22-q23 efg, Cmyb, c-myb, c-myb_CDS -MYB and Breast Cancer
58
TTPA 8q12.3 ATTP, AVED, TTP1, alphaTTP -TTPA and Breast Cancer
57
IGF2R 6q26 MPR1, MPRI, CD222, CIMPR, M6P-R -IGF2R and Breast Cancer
56
FGFR1 8p11.23-p11.22 CEK, FLG, HH2, OGD, FLT2, KAL2, BFGFR, CD331, FGFBR, FLT-2, HBGFR, N-SAM, FGFR-1, HRTFDS, bFGF-R-1 -FGFR1 and Breast Cancer
56
AURKA 20q13 AIK, ARK1, AURA, BTAK, STK6, STK7, STK15, AURORA2, PPP1R47 -AURKA and Breast Cancer
55
NBN 8q21 ATV, NBS, P95, NBS1, AT-V1, AT-V2 -NBN and Breast Cancer
54
MAP3K1 5q11.2 MEKK, MEKK1, SRXY6, MEKK 1, MAPKKK1 -MAP3K1 and Breast Cancer
53
NCOA3 20q12 ACTR, AIB1, RAC3, SRC3, pCIP, AIB-1, CTG26, SRC-3, CAGH16, KAT13B, TNRC14, TNRC16, TRAM-1, bHLHe42 -NCOA3 and Breast Cancer
53
ERCC2 19q13.3 EM9, TTD, XPD, COFS2, TFIIH -ERCC2 and Breast Cancer
52
TFAP2A 6p24 AP-2, BOFS, AP2TF, TFAP2, AP-2alpha -TFAP2A Expression in Breast Cancer
51
IGF2 11p15.5 IGF-II, PP9974, C11orf43 -IGF2 and Breast Cancer
51
ACHE 7q22 YT, ACEE, ARACHE, N-ACHE -ACHE and Breast Cancer
51
TFAP2B 6p12 AP-2B, AP2-B -TFAP2B and Breast Cancer
50
TFAP2C 20q13.2 ERF1, TFAP2G, hAP-2g, AP2-GAMMA -TFAP2C and Breast Cancer
50
RHOA 3p21.3 ARHA, ARH12, RHO12, RHOH12 -RHOA and Breast Cancer
50
RELA 11q13 p65, NFKB3 -RELA and Breast Cancer
50
EZH2 7q35-q36 WVS, ENX1, EZH1, KMT6, WVS2, ENX-1, EZH2b, KMT6A -EZH2 and Breast Cancer
49
IL6 7p21 HGF, HSF, BSF2, IL-6, IFNB2 -IL6 and Breast Cancer
48
SMAD4 18q21.1 JIP, DPC4, MADH4, MYHRS -SMAD4 and Breast Cancer
47
FH 1q42.1 MCL, LRCC, HLRCC, MCUL1 -FH and Breast Cancer
47
RAC1 7p22 MIG5, Rac-1, TC-25, p21-Rac1 -RAC1 and Breast Cancer
47
HSD17B2 16q24.1-q24.2 HSD17, SDR9C2, EDH17B2 -HSD17B2 and Breast Cancer
47
DNMT1 19p13.2 AIM, DNMT, MCMT, CXXC9, HSN1E, ADCADN -DNMT1 and Breast Cancer
46
H2AFX 11q23.3 H2AX, H2A.X, H2A/X -H2AFX and Breast Cancer
46
WNT1 12q13 INT1, OI15, BMND16 -WNT1 and Breast Cancer
46
RAD50 5q31 NBSLD, RAD502, hRad50 -RAD50 and Breast Cancer
45
EPCAM 2p21 ESA, KSA, M4S1, MK-1, DIAR5, EGP-2, EGP40, KS1/4, MIC18, TROP1, EGP314, HNPCC8, TACSTD1 -EPCAM and Breast Cancer
45
ZEB1 10p11.2 BZP, TCF8, AREB6, FECD6, NIL2A, PPCD3, ZFHEP, ZFHX1A, DELTAEF1 -ZEB1 and Breast Cancer
45
STK11 19p13.3 PJS, LKB1, hLKB1 -STK11 and Breast Cancer
44
SHBG 17p13.1 ABP, SBP, TEBG -SHBG and Breast Cancer
44
LSP1 11p15.5 WP34, pp52 -LSP1 and Breast Cancer
43
ITGB1 10p11.2 CD29, FNRB, MDF2, VLAB, GPIIA, MSK12, VLA-BETA -ITGB1 (CD29) and Breast Cancer
42
GRB7 17q12 -GRB7 and Breast Cancer
41
TNFRSF11A 18q22.1 FEO, OFE, ODFR, OSTS, PDB2, RANK, CD265, OPTB7, TRANCER, LOH18CR1 -TNFRSF11A and Breast Cancer
41
GAPDH 12p13 G3PD, GAPD, HEL-S-162eP -GAPDH and Breast Cancer
41
HGF 7q21.1 SF, HGFB, HPTA, F-TCF, DFNB39 -HGF and Breast Cancer
41
HDAC1 1p34 HD1, RPD3, GON-10, RPD3L1 -HDAC1 and Breast Cancer
41
NQO1 16q22.1 DTD, QR1, DHQU, DIA4, NMOR1, NMORI -NQO1 and Breast Cancer
40
ABCC1 16p13.1 MRP, ABCC, GS-X, MRP1, ABC29 -ABCC1 (MRP1) and Breast Cancer
40
TGFBR2 3p22 AAT3, FAA3, LDS2, MFS2, RIIC, LDS1B, LDS2B, TAAD2, TGFR-2, TGFbeta-RII -TGFBR2 and Breast Cancer
40
TNFRSF10B 8p22-p21 DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5 -TNFRSF10B and Breast Cancer
40
RAD51C 17q22 FANCO, R51H3, BROVCA3, RAD51L2 -RAD51C and Breast Cancer
40
ERBB4 2q33.3-q34 HER4, ALS19, p180erbB4 -ERBB4 and Breast Cancer
40
IGF1 12q23.2 IGFI, IGF-I, IGF1A -IGF1 and Breast Cancer
40
SOD2 6q25.3 IPOB, MNSOD, MVCD6 -SOD2 and Breast Cancer
39
TOX3 16q12.1 CAGF9, TNRC9 -TOX3 and Breast Cancer
39
NTRK3 15q25 TRKC, gp145(trkC) Translocation
-NTRK3 and Breast Cancer
-t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
32
CYP1A2 15q24.1 CP12, P3-450, P450(PA) -CYP1A2 and Breast Cancer
37
VEGFC 4q34.3 VRP, Flt4-L, LMPH1D -VEGFC and Breast Cancer
37
CDC42 1p36.1 G25K, CDC42Hs -CDC42 and Breast Cancer
37
CAV1 7q31.1 CGL3, PPH3, BSCL3, LCCNS, VIP21, MSTP085 -CAV1 and Breast Cancer
36
PARL 3q27.1 PSARL, PSARL1, RHBDS1, PRO2207, PSENIP2 -PARL and Breast Cancer
35
BACH1 21q22.11 BACH-1, BTBD24 -BACH1 and Breast Cancer
35
STAT1 2q32.2 CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91 -STAT1 and Breast Cancer
35
CYP3A5 7q21.1 CP35, PCN3, CYPIIIA5, P450PCN3 -CYP3A5 and Breast Cancer
34
CCND2 12p13 MPPH3, KIAK0002 -CCND2 and Breast Cancer
34
BRMS1 11q13-q13.2 -BRMS1 and Breast Cancer
33
CYP2C19 10q24 CPCJ, CYP2C, P450C2C, CYPIIC17, CYPIIC19, P450IIC19 -CYP2C19 and Breast Cancer
33
ALDH1A1 9q21.13 ALDC, ALDH1, HEL-9, HEL12, PUMB1, ALDH11, RALDH1, ALDH-E1, HEL-S-53e -ALDH1A1 and Breast Cancer
32
OLAH 10p13 SAST, AURA1, THEDC1 -OLAH and Breast Cancer
32
PDGFB 22q13.1 SIS, SSV, IBGC5, PDGF2, c-sis, PDGF-2 -PDGFB and Breast Cancer
32
CTCF 16q21-q22.3 MRD21 -CTCF and Breast Cancer
31
S100A4 1q21 42A, 18A2, CAPL, FSP1, MTS1, P9KA, PEL98 -S100A4 and Breast Cancer
31
PRLR 5p13.2 HPRL, MFAB, hPRLrI -PRLR and Breast Cancer
31
BAG1 9p12 HAP, BAG-1, RAP46 Overexpression
-BAG1 overexpression in Breast Cancer
31
PTK2 8q24.3 FAK, FADK, FAK1, FRNK, PPP1R71, p125FAK, pp125FAK -PTK2 and Breast Cancer
30
LIMK1 7q11.23 LIMK, LIMK-1 -LIMK1 and Breast Cancer
30
XRCC2 7q36.1 -XRCC2 and Breast Cancer
30
FAS 10q24.1 APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6 -FAS and Breast Cancer
30
MTA1 14q32.3 -MTA1 and Breast Cancer
30
SMAD2 18q21.1 JV18, MADH2, MADR2, JV18-1, hMAD-2, hSMAD2 -SMAD2 and Breast Cancer
30
IRS1 2q36 HIRS-1 -IRS1 and Breast Cancer
30
CDC25A 3p21 CDC25A2 -CDC25A and Breast Cancer
30
EIF4E 4q23 CBP, EIF4F, AUTS19, EIF4E1, EIF4EL1 -EIF4E and Breast Cancer
29
CXCL1 4q21 FSP, GRO1, GROa, MGSA, NAP-3, SCYB1, MGSA-a -CXCL1 and Breast Cancer
29
SFRP1 8p11.21 FRP, FRP1, FrzA, FRP-1, SARP2 -SFRP1 and Breast Cancer
29
MMP3 11q22.3 SL-1, STMY, STR1, CHDS6, MMP-3, STMY1 -MMP3 and Breast Cancer
29
CD82 11p11.2 R2, 4F9, C33, IA4, ST6, GR15, KAI1, SAR2, TSPAN27 -CD82 and Breast Cancer
28
TIMP2 17q25 DDC8, CSC-21K, KIAA1731NL Prognostic
-TIMP2 Expression in Breast Cancer
28
JUNB 19p13.2 AP-1 -JUNB and Breast Cancer
28
CHIA 1p13.2 CHIT2, AMCASE, TSA1902 -CHIA and Breast Cancer
28
FOXO3 6q21 FOXO2, AF6q21, FKHRL1, FOXO3A, FKHRL1P2 -FOXO3 and Breast Cancer
28
FOXM1 12p13 MPP2, TGT3, HFH11, HNF-3, INS-1, MPP-2, PIG29, FKHL16, FOXM1B, HFH-11, TRIDENT, MPHOSPH2 -FOXM1 and Breast Cancer
28
WWOX 16q23 FOR, WOX1, FRA16D, SCAR12, HHCMA56, PRO0128, SDR41C1, D16S432E -WWOX and Breast Cancer
28
GPER1 7p22.3 mER, CEPR, GPER, DRY12, FEG-1, GPR30, LERGU, LyGPR, CMKRL2, LERGU2, GPCR-Br -GPER and Breast Cancer
28
TNFSF11 13q14 ODF, OPGL, sOdf, CD254, OPTB2, RANKL, TRANCE, hRANKL2 -TNFSF11 and Breast Cancer
27
EGR1 5q31.1 TIS8, AT225, G0S30, NGFI-A, ZNF225, KROX-24, ZIF-268 -EGR1 and Breast Cancer
27
JUND 19p13.2 AP-1 -JUND and Breast Cancer
27
NCOA1 2p23 SRC1, KAT13A, RIP160, F-SRC-1, bHLHe42, bHLHe74 -NCOA1 and Breast Cancer
27
PLAUR 19q13 CD87, UPAR, URKR, U-PAR -PLAUR and Breast Cancer
27
PIN1 19p13 DOD, UBL5 -PIN1 and Breast Cancer
26
COIL 17q22 CLN80, p80-coilin -COIL and Breast Cancer
26
TERC 3q26 TR, hTR, TRC3, DKCA1, PFBMFT2, SCARNA19 -TERC and Breast Cancer
26
MMP1 11q22.3 CLG, CLGN -MMP1 and Breast Cancer
26
THBS1 15q15 TSP, THBS, TSP1, TSP-1, THBS-1 -THBS1 and Breast Cancer
26
PTTG1 5q35.1 EAP1, PTTG, HPTTG, TUTR1 -PTTG1 and Breast Cancer
26
XPC 3p25.1 XP3, RAD4, XPCC, p125 -XPC and Breast Cancer
26
PRKCA 17q22-q23.2 AAG6, PKCA, PRKACA, PKC-alpha -PRKCA and Breast Cancer
26
FOXP3 Xp11.23 JM2, AIID, IPEX, PIDX, XPID, DIETER -FOXP3 and Breast Cancer
26
ANXA8 10q11.22 ANX8 -ANXA8 and Breast Cancer
26
DNMT3B 20q11.2 ICF, ICF1, M.HsaIIIB -DNMT3B and Breast Cancer
26
CTGF 6q23.1 CCN2, NOV2, HCS24, IGFBP8 -CTGF and Breast Cancer
26
STAR 8p11.2 STARD1 -STAR and Breast Cancer
25
LGALS3 14q22.3 L31, GAL3, MAC2, CBP35, GALBP, GALIG, LGALS2 -LGALS3 and Breast Cancer
25
CCNE1 19q12 CCNE -CCNE1 and Breast Cancer
25
MAF 16q22-q23 CCA4, c-MAF -MAF and Breast Cancer
25
MMP11 22q11.23 ST3, SL-3, STMY3 Prognostic
-MMP11 Expression in Breast Cancer
25
MCAM 11q23.3 CD146, MUC18 -MCAM and Breast Cancer
25
BECN1 17q21 ATG6, VPS30, beclin1 -BECN1 and Breast Cancer
24
DROSHA 5p13.3 RN3, ETOHI2, RNASEN, RANSE3L, RNASE3L, HSA242976 -DROSHA and Breast Cancer
24
SKP2 5p13 p45, FBL1, FLB1, FBXL1 -SKP2 and Breast Cancer
24
FGF4 11q13.3 HST, KFGF, HST-1, HSTF1, K-FGF, HBGF-4 -FGF4 and Breast Cancer
24
PECAM1 17q23.3 CD31, PECA1, GPIIA', PECAM-1, endoCAM, CD31/EndoCAM -PECAM1 and Breast Cancer
24
ESR2 14q23.2 Erb, ESRB, ESTRB, NR3A2, ER-BETA, ESR-BETA -ESR2 and Breast Cancer
24
PPP2CB 8p12 PP2CB, PP2Abeta -PPP2CB and Breast Cancer
24
SPARC 5q31.3-q32 ON -SPARC and Breast Cancer
24
SYK 9q22 p72-Syk -SYK and Breast Cancer
24
GRB2 17q24-q25 ASH, Grb3-3, MST084, NCKAP2, MSTP084, EGFRBP-GRB2 -GRB2 and Breast Cancer
24
TSG101 11p15 TSG10, VPS23 -TSG101 and Breast Cancer
24
SOX2 3q26.3-q27 ANOP3, MCOPS3 -SOX2 and Breast Cancer
24
BCAR1 16q23.1 CAS, CAS1, CASS1, CRKAS, P130Cas -BCAR1 and Breast Cancer
24
TIMP3 22q12.3 SFD, K222, K222TA2, HSMRK222 -TIMP3 and Breast Cancer
24
NRG1 8p12 GGF, HGL, HRG, NDF, ARIA, GGF2, HRG1, HRGA, SMDF, MST131, MSTP131, NRG1-IT2 -NRG1 and Breast Cancer
23
SLC2A1 1p34.2 PED, DYT9, GLUT, DYT17, DYT18, EIG12, GLUT1, HTLVR, GLUT-1, GLUT1DS -GLUT1 expression in Breast Cancer
23
TYMS 18p11.32 TS, TMS, HST422 -TYMS and Breast Cancer
23
MDM4 1q32 HDMX, MDMX, MRP1 -MDM4 and Breast Cancer
23
PPP2CA 5q31.1 RP-C, PP2Ac, PP2CA, PP2Calpha -PPP2CA and Breast Cancer
23
SIRT1 10q21.3 SIR2L1 -SIRT1 and Breast Cancer
23
FGFR4 5q35.2 TKF, JTK2, CD334 -FGFR4 and Breast Cancer
23
HSD17B1 17q11-q21 HSD17, EDHB17, EDH17B2, SDR28C1 -HSD17B1 and Breast Cancer
23
E2F4 16q22.1 E2F-4 -E2F4 and Breast Cancer
22
ZNF217 20q13.2 ZABC1 -ZNF217 and Breast Cancer
22
NAT1 8p22 AAC1, MNAT, NATI, NAT-1 -NAT1 and Breast Cancer
22
ARHGEF1 19q13.13 LSC, GEF1, LBCL2, SUB1.5, P115-RHOGEF -ARHGEF1 and Breast Cancer
22
SCGB3A1 5q35.3 HIN1, HIN-1, LU105, UGRP2, PnSP-2 -SCGB3A1 and Breast Cancer
22
PAK1 11q13-q14 PAKalpha -PAK1 and Breast Cancer
22
RUNX2 6p21 CCD, AML3, CCD1, CLCD, OSF2, CBFA1, OSF-2, PEA2aA, PEBP2aA, CBF-alpha-1 -RUNX2 and Breast Cancer
22
PDCD4 10q24 H731 -PDCD4 and Breast Cancer
21
HEBP1 12p13.1 HBP, HEBP -HEBP1 and Breast Cancer
21
MIB1 18q11.2 MIB, DIP1, ZZZ6, DIP-1, LVNC7, ZZANK2 -MIB1 and Breast Cancer
21
BUB1 2q14 BUB1A, BUB1L, hBUB1 -BUB1 and Breast Cancer
21
CLOCK 4q12 KAT13D, bHLHe8 -CLOCK and Breast Cancer
21
CASP7 10q25 MCH3, CMH-1, LICE2, CASP-7, ICE-LAP3 -CASP7 and Breast Cancer
21
CYP2B6 19q13.2 CPB6, EFVM, IIB1, P450, CYP2B, CYP2B7, CYP2B7P, CYPIIB6 -CYP2B6 and Breast Cancer
21
CYP2C9 10q24 CPC9, CYP2C, CYP2C10, CYPIIC9, P450IIC9 -CYP2C9 and Breast Cancer
21
PTHLH 12p12.1-p11.2 HHM, PLP, BDE2, PTHR, PTHRP -PTHLH and Breast Cancer
21
TP53BP1 15q15-q21 p202, 53BP1 -TP53BP1 and Breast Cancer
21
NFE2L2 2q31 NRF2 -NFE2L2 and Breast Cancer
21
RAD52 12p13-p12.2 -RAD52 and Breast Cancer
21
PLK1 16p12.2 PLK, STPK13 -PLK1 and Breast Cancer
21
TRPM2 21q22.3 KNP3, EREG1, TRPC7, LTRPC2, NUDT9H, NUDT9L1 -TRPM2 and Breast Cancer
21
KISS1 1q32 HH13, KiSS-1 -KISS1 and Breast Cancer
21
RAP1A 1p13.3 RAP1, C21KG, G-22K, KREV1, KREV-1, SMGP21 -Breast Cancer and RAP1A
20
CCNA2 4q27 CCN1, CCNA -CCNA2 and Breast Cancer
20
TFF3 21q22.3 ITF, P1B, TFI -TFF3 and Breast Cancer
20
WNT5A 3p21-p14 hWNT5A -WNT5A and Breast Cancer
20
STAT5A 17q11.2 MGF, STAT5 -STAT5A and Breast Cancer
20
CST6 11q13 -CST6 and Breast Cancer
20
NCOR1 17p11.2 N-CoR, TRAC1, N-CoR1, hN-CoR, PPP1R109 -NCOR1 and Breast Cancer
20
ELAVL1 19p13.2 HUR, Hua, MelG, ELAV1 -ELAVL1 and Breast Cancer
20
TP63 3q28 AIS, KET, LMS, NBP, RHS, p40, p51, p63, EEC3, OFC8, p73H, p73L, SHFM4, TP53L, TP73L, p53CP, TP53CP, B(p51A), B(p51B) -TP63 and Breast Cancer
20
PTK6 20q13.3 BRK -PTK6 and Breast Cancer
20
LEPR 1p31 OBR, OB-R, CD295, LEP-R, LEPRD -LEPR and Breast Cancer
20
EPHA2 1p36 ECK, CTPA, ARCC2, CTPP1, CTRCT6 -EPHA2 and Breast Cancer
20
SNCG 10q23.2-q23.3 SR, BCSG1 -SNCG and Breast Cancer
20
OSCAR 19q13.42 PIGR3, PIgR-3 -OSCAR and Breast Cancer
20
ZEB2 2q22.3 SIP1, SIP-1, ZFHX1B, HSPC082, SMADIP1 -ZEB2 and Breast Cancer
20
LOX 5q23.2 -LOX and Breast Cancer
20
CCL2 17q11.2-q12 HC11, MCAF, MCP1, MCP-1, SCYA2, GDCF-2, SMC-CF, HSMCR30 -CCL2 and Breast Cancer
20
DIRAS3 1p31 ARHI, NOEY2 -DIRAS3 and Breast Cancer
20
CRK 17p13.3 p38, CRKII -CRK and Breast Cancer
20
MIR126 9q34.3 MIRN126, miRNA126 -MicroRNA mir-126 and Breast Cancer
19
NOS3 7q36 eNOS, ECNOS -NOS3 and Breast Cancer
19
POLL 10q23 BETAN, POLKAPPA -POLL and Breast Cancer
19
CD9 12p13.3 MIC3, MRP-1, BTCC-1, DRAP-27, TSPAN29, TSPAN-29 -CD9 expression in Breast Cancer
19
MRE11A 11q21 ATLD, HNGS1, MRE11, MRE11B -MRE11A and Breast Cancer
19
SPP1 4q22.1 OPN, BNSP, BSPI, ETA-1 -SPP1 and Breast Cancer
19
CLU 8p21-p12 CLI, AAG4, APOJ, CLU1, CLU2, KUB1, SGP2, APO-J, SGP-2, SP-40, TRPM2, TRPM-2, NA1/NA2 -CLU and Breast Cancer
19
MTDH 8q22.1 3D3, AEG1, AEG-1, LYRIC, LYRIC/3D3 -MTDH and Breast Cancer
19
GSTA1 6p12.1 GST2, GTH1, GSTA1-1 -GSTA1 and Breast Cancer
19
M6PR 12p13 SMPR, MPR46, CD-MPR, MPR 46, MPR-46 -M6PR and Breast Cancer
19
FBXW7 4q31.3 AGO, CDC4, FBW6, FBW7, hAgo, FBX30, FBXW6, SEL10, hCdc4, FBXO30, SEL-10 -FBXW7 and Breast Cancer
19
DDIT3 12q13.1-q13.2 CHOP, CEBPZ, CHOP10, CHOP-10, GADD153 -DDIT3 and Breast Cancer
19
ID2 2p25 GIG8, ID2A, ID2H, bHLHb26 -ID2 Expression in Breast Cancer
18
EIF4EBP1 8p12 BP-1, 4EBP1, 4E-BP1, PHAS-I -EIF4EBP1 and Breast Cancer
18
IGFBP1 7p12.3 AFBP, IBP1, PP12, IGF-BP25, hIGFBP-1 -IGFBP1 and Breast Cancer
18
APOE 19q13.2 AD2, LPG, APO-E, LDLCQ5 -APOE and Breast Cancer
18
FGF1 5q31 AFGF, ECGF, FGFA, ECGFA, ECGFB, FGF-1, HBGF1, HBGF-1, GLIO703, ECGF-beta, FGF-alpha -FGF1 and Breast Cancer
18
CTTN 11q13 EMS1 -CTTN and Breast Cancer
18
TNFRSF11B 8q24 OPG, TR1, OCIF -TNFRSF11B and Breast Cancer
18
HMOX1 22q13.1 HO-1, HSP32, HMOX1D, bK286B10 -HMOX1 and Breast Cancer
18
PPM1D 17q23.2 WIP1, PP2C-DELTA -PPM1D and Breast Cancer
18
S100A7 1q21 PSOR1, S100A7c -S100A7 and Breast Cancer
18
NOTCH3 19p13.2-p13.1 IMF2, CASIL, CADASIL -NOTCH3 and Breast Cancer
18
EP300 22q13.2 p300, KAT3B, RSTS2 -EP300 and Breast Cancer
18
ELK1 Xp11.2 -ELK1 and Breast Cancer
17
TCF7L2 10q25.3 TCF4, TCF-4 -TCF7L2 and Breast Cancer
17
ERCC4 16p13.12 XPF, RAD1, FANCQ, ERCC11 -ERCC4 and Breast Cancer
17
POLE 12q24.3 FILS, POLE1, CRCS12 -POLE and Breast Cancer
17
HIC1 17p13.3 hic-1, ZBTB29, ZNF901 -HIC1 and Breast Cancer
17
NANOG 12p13.31 -NANOG and Breast Cancer
17
CSK 15q24.1 -CSK and Breast Cancer
17
CDC25C 5q31 CDC25, PPP1R60 -CDC25C and Breast Cancer
17
MECP2 Xq28 RS, RTS, RTT, PPMX, MRX16, MRX79, MRXSL, AUTSX3, MRXS13 -MECP2 and Breast Cancer
17
NOTCH2 1p13-p11 hN2, AGS2, HJCYS -NOTCH2 and Breast Cancer
17
FTCDNL1 2q33.1 FONG -FONG and Breast Cancer
17
XRCC4 5q14.2 -XRCC4 and Breast Cancer
17
ETS2 21q22.2 ETS2IT1 -ETS2 and Breast Cancer
17
PITX2 4q25 RS, RGS, ARP1, Brx1, IDG2, IGDS, IHG2, PTX2, RIEG, IGDS2, IRID2, Otlx2, RIEG1 -PITX2 and Breast Cancer
16
CDH13 16q23.3 CDHH, P105 -CDH13 and Breast Cancer
16
POU5F1 6p21.31 OCT3, OCT4, OTF3, OTF4, OTF-3, Oct-3, Oct-4 -POU5F1 and Breast Cancer
16
SCFV 14 -SCFV and Breast Cancer
16
OGG1 3p26.2 HMMH, MUTM, OGH1, HOGG1 -OGG1 and Breast Cancer
16
HFE 6p21.3 HH, HFE1, HLA-H, MVCD7, TFQTL2 -HFE and Breast Cancer
16
STAT5B 17q11.2 STAT5 -STAT5B and Breast Cancer
16
DNMT3A 2p23 TBRS, DNMT3A2, M.HsaIIIA -DNMT3A and Breast Cancer
16
CREBBP 16p13.3 CBP, RSTS, KAT3A -CREBBP and Breast Cancer
16
MYBL2 20q13.1 BMYB, B-MYB -MYBL2 and Breast Cancer
16
AGR2 7p21.3 AG2, GOB-4, HAG-2, XAG-2, PDIA17, HEL-S-116 -AGR2 and Breast Cancer
16
SATB1 3p23 -SATB1 and Breast Cancer
16
MMP14 14q11.2 MMP-14, MMP-X1, MT-MMP, MT1MMP, MTMMP1, WNCHRS, MT1-MMP, MT-MMP 1 -MMP14 and Breast Cancer
16
MTRR 5p15.31 MSR, cblE -MTRR and Breast Cancer
16
MMP13 11q22.3 CLG3, MANDP1, MMP-13 -MMP13 and Breast Cancer
16
CCL5 17q12 SISd, eoCP, SCYA5, RANTES, TCP228, D17S136E, SIS-delta -CCL5 and Breast Cancer
15
BBC3 19q13.3-q13.4 JFY1, PUMA, JFY-1 -BBC3 and Breast Cancer
15
KRT5 12q13.13 K5, CK5, DDD, DDD1, EBS2, KRT5A -KRT5 and Breast Cancer
15
TIAM1 21q22.11 -TIAM1 and Breast Cancer
15
GPX1 3p21.3 GPXD, GSHPX1 -GPX1 and Breast Cancer
15
CCND3 6p21 -CCND3 and Breast Cancer
15
CTNNA1 5q31.2 CAP102 -CTNNA1 and Breast Cancer
15
RARB 3p24.2 HAP, RRB2, NR1B2, MCOPS12 -RARB and Breast Cancer
15
PELP1 17p13.2 MNAR, P160 -PELP1 and Breast Cancer
15
CREB1 2q34 CREB -CREB1 and Breast Cancer
15
AKT3 1q44 MPPH, PKBG, MPPH2, PRKBG, STK-2, PKB-GAMMA, RAC-gamma, RAC-PK-gamma -AKT3 and Breast Cancer
15
KLF4 9q31 EZF, GKLF -KLF4 and Breast Cancer
15
APOD 3q29 -APOD and Breast Cancer
15
CTLA4 2q33 CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3 -CTLA4 and Breast Cancer
15
WISP2 20q13.12 CCN5, CT58, CTGF-L -WISP2 and Breast Cancer
15
ITGB4 17q25 CD104 -ITGB4 and Breast Cancer
15
SSTR2 17q24 -SSTR2 and Breast Cancer
14
IL11 19q13.3-q13.4 AGIF, IL-11 -IL11 and Breast Cancer
14
DLX4 17q21.33 BP1, DLX7, DLX8, DLX9 -DLX4 and Breast Cancer
14
SPDEF 6p21.3 PDEF, bA375E1.3 -SPDEF and Breast Cancer
14
ZNF350 19q13.41 ZFQR, ZBRK1 -ZNF350 and Breast Cancer
14
WNT3 17q21 INT4 -WNT3 and Breast Cancer
14
NEK2 1q32.3 NLK1, RP67, NEK2A, HsPK21, PPP1R111 -NEK2 and Breast Cancer
14
FES 15q26.1 FPS -FES and Breast Cancer
14
ACTB 7p22 BRWS1, PS1TP5BP1 -ACTB and Breast Cancer
14
DLC1 8p22 HP, ARHGAP7, STARD12, p122-RhoGAP -Breast Cancer and DLC1
14
PIK3CB 3q22.3 PI3K, PIK3C1, P110BETA, PI3KBETA -PIK3CB and Breast Cancer
14
CLDN1 3q28-q29 CLD1, SEMP1, ILVASC -CLDN1 and Breast Cancer
14
CDK1 10q21.1 CDC2, CDC28A, P34CDC2 -CDK1 and Breast Cancer
14
MIRLET7B 22q13.31 LET7B, let-7b, MIRNLET7B, hsa-let-7b -MicroRNA let-7b and Breast Cancer
14
CYP27B1 12q14.1 VDR, CP2B, CYP1, PDDR, VDD1, VDDR, VDDRI, CYP27B, P450c1, CYP1alpha -CYP27B1 and Breast Cancer
14
REL 2p13-p12 C-Rel -REL and Breast Cancer
14
TNFRSF10A 8p21 DR4, APO2, CD261, TRAILR1, TRAILR-1 -TNFRSF10A and Breast Cancer
14
TGFB2 1q41 LDS4, TGF-beta2 -TGFB2 and Breast Cancer
14
NCOR2 12q24 SMRT, TRAC, CTG26, SMRTE, TRAC1, N-CoR2, TNRC14, TRAC-1, SMAP270, SMRTE-tau -NCOR2 and Breast Cancer
14
CYR61 1p22.3 CCN1, GIG1, IGFBP10 -CYR61 and Breast Cancer
14
YBX1 1p34 YB1, BP-8, CSDB, DBPB, YB-1, CSDA2, NSEP1, NSEP-1, MDR-NF1 -YBX1 and Breast Cancer
14
ARNT 1q21 HIF1B, TANGO, bHLHe2, HIF1BETA, HIF-1beta, HIF1-beta, HIF-1-beta -ARNT and Breast Cancer
14
RELB 19q13.32 IREL, I-REL, REL-B -RELB and Breast Cancer
14
IGFBP5 2q35 IBP5 -IGFBP5 and Breast Cancer
14
TLR4 9q33.1 TOLL, CD284, TLR-4, ARMD10 -TLR4 and Breast Cancer
14
KLK10 19q13 NES1, PRSSL1 -KLK10 and Breast Cancer
14
NOS2 17q11.2 NOS, INOS, NOS2A, HEP-NOS -NOS2 and Breast Cancer
14
CXCL2 4q21 GRO2, GROb, MIP2, MIP2A, SCYB2, MGSA-b, MIP-2a, CINC-2a -CXCL2 and Breast Cancer
14
MARCO 2q14.2 SCARA2 -MARCO and Breast Cancer
14
GREB1 2p25.1 -GREB1 and Breast Cancer
13
JAG1 20p12.1-p11.23 AGS, AHD, AWS, HJ1, CD339, JAGL1 -JAG1 and Breast Cancer
13
MBD2 18q21 DMTase, NY-CO-41 -MBD2 and Breast Cancer
13
UBE2C 20q13.12 UBCH10, dJ447F3.2 -UBE2C and Breast Cancer
13
HSPB1 7q11.23 CMT2F, HMN2B, HSP27, HSP28, Hsp25, SRP27, HS.76067, HEL-S-102 -HSPB1 and Breast Cancer
13
RAD51D 17q11 TRAD, R51H3, BROVCA4, RAD51L3 -RAD51D and Breast Cancer
13
GADD45A 1p31.2 DDIT1, GADD45 -GADD45A and Breast Cancer
13
IGFBP4 17q21.2 BP-4, IBP4, IGFBP-4, HT29-IGFBP -IGFBP4 and Breast Cancer
13
MOS 8q11 MSV -MOS and Breast Cancer
13
RHOB 2p24 ARH6, ARHB, RHOH6, MST081, MSTP081 -RHOB and Breast Cancer
13
PDK1 2q31.1 -PDK1 and Breast Cancer
13
WISP3 6q21 PPD, CCN6, LIBC, PPAC -WISP3 and Breast Cancer
13
FOXC1 6p25 ARA, IGDA, IHG1, FKHL7, IRID1, RIEG3, FREAC3, FREAC-3 -FOXC1 and Breast Cancer
13
MAD2L1 4q27 MAD2, HSMAD2 -MAD2L1 and Breast Cancer
13
HDAC3 5q31 HD3, RPD3, RPD3-2 -HDAC3 and Breast Cancer
13
E2F3 6p22 E2F-3 -E2F3 and Breast Cancer
13
NOTCH4 6p21.3 INT3 -NOTCH4 and Breast Cancer
13
VIP 6q25 PHM27 -VIP and Breast Cancer
13
BNIP3 10q26.3 NIP3 -BNIP3 and Breast Cancer
13
PWAR1 15q11.2 PAR1, PAR-1, D15S227E -PAR1 and Breast Cancer
12
CYP24A1 20q13 CP24, HCAI, CYP24, P450-CC24 -CYP24A1 and Breast Cancer
12
SIX1 14q23.1 BOS3, TIP39, DFNA23 -SIX1 and Breast Cancer
12
SNAI1 20q13.2 SNA, SNAH, SNAIL, SLUGH2, SNAIL1, dJ710H13.1 -SNAI1 and Breast Cancer
12
FYN 6q21 SLK, SYN, p59-FYN -FYN and Breast Cancer
12
RFC1 4p14-p13 A1, RFC, PO-GA, RECC1, MHCBFB, RFC140 -RFC1 and Breast Cancer
12
SHC1 1q21 SHC, SHCA -SHC1 and Breast Cancer
12
RRM2 2p25-p24 R2, RR2, RR2M -RRM2 and Breast Cancer
12
SIPA1 11q13 SPA1 -SIPA1 and Breast Cancer
12
SMAD7 18q21.1 CRCS3, MADH7, MADH8 -SMAD7 and Breast Cancer
12
NFKB1 4q24 p50, KBF1, p105, EBP-1, NF-kB1, NFKB-p50, NFkappaB, NF-kappaB, NFKB-p105, NF-kappa-B -NFKB1 and Breast Cancer
12
CARM1 19p13.2 PRMT4 -CARM1 and Breast Cancer
12
FASN 17q25 FAS, OA-519, SDR27X1 -FASN and Breast Cancer
12
PARK2 6q25.2-q27 PDJ, PRKN, AR-JP, LPRS2 -PARK2 and Breast Cancer
12
TOPBP1 3q22.1 TOP2BP1 -TOPBP1 and Breast Cancer
12
RAD51B 14q23-q24.2 REC2, R51H2, RAD51L1 -RAD51B and Breast Cancer
12
SNAI2 8q11 SLUG, WS2D, SLUGH1, SNAIL2 -SNAI2 and Breast Cancer
12
RAD21 8q24 HR21, MCD1, NXP1, SCC1, CDLS4, hHR21, HRAD21 -RAD21 and Breast Cancer
12
VIM 10p13 HEL113, CTRCT30 -VIM and Breast Cancer
12
KDR 4q11-q12 FLK1, CD309, VEGFR, VEGFR2 -KDR and Breast Cancer
12
AMPH 7p14-p13 AMPH1 Overexpression
-AMPH Expression in Stiff-Person Syndrome associated Breast Cancer
12
SRD5A2 2p23 -SRD5A2 and Breast Cancer
12
PRKDC 8q11 HYRC, p350, DNAPK, DNPK1, HYRC1, IMD26, XRCC7, DNA-PKcs -PRKDC and Breast Cancer
11
ANXA5 4q27 PP4, ANX5, ENX2, RPRGL3, HEL-S-7 -ANXA5 and Breast Cancer
11
GDF15 19p13.11 PDF, MIC1, PLAB, MIC-1, NAG-1, PTGFB, GDF-15 -GDF15 and Breast Cancer
11
BAP1 3p21.31-p21.2 UCHL2, hucep-6, HUCEP-13 -BAP1 and Breast Cancer
11
RPS6KB1 17q23.1 S6K, PS6K, S6K1, STK14A, p70-S6K, p70 S6KA, p70-alpha, S6K-beta-1, p70(S6K)-alpha -RPS6KB1 and Breast Cancer
11
LMO4 1p22.3 -LMO4 and Breast Cancer
11
PIGS 17p13.2 -PIGS and Breast Cancer
11
HDAC6 Xp11.23 HD6, JM21, CPBHM, PPP1R90 -HDAC6 and Breast Cancer
11
BTG2 1q32 PC3, TIS21 -BTG2 and Breast Cancer
11
CAST 5q15 BS-17 -CAST and Breast Cancer
11
TACSTD2 1p32 EGP1, GP50, M1S1, EGP-1, TROP2, GA7331, GA733-1 -TACSTD2 and Breast Cancer
11
IRS2 13q34 IRS-2 -IRS2 and Breast Cancer
11
ALCAM 3q13.1 MEMD, CD166 -ALCAM and Breast Cancer
11
EIF3E 8q22-q23 INT6, EIF3S6, EIF3-P48, eIF3-p46 -EIF3E and Breast Cancer
11
TRPS1 8q24.12 GC79, LGCR -TRPS1 and Breast Cancer
11
SERPINB5 18q21.33 PI5, maspin -SERPINB5 and Breast Cancer
11
AKR1C3 10p15-p14 DD3, DDX, PGFS, HAKRB, HAKRe, HA1753, HSD17B5, hluPGFS -AKR1C3 and Breast Cancer
11
TPM3 1q21.2 TM3, TM5, TRK, CFTD, NEM1, TM-5, TM30, CAPM1, TM30nm, TPMsk3, hscp30, HEL-189, HEL-S-82p, OK/SW-cl.5 -TPM3 and Breast Cancer
11
AREG 4q13.3 AR, SDGF, AREGB, CRDGF -AREG and Breast Cancer
11
HOXB7 17q21.3 HOX2, HOX2C, HHO.C1, Hox-2.3 -HOXB7 and Breast Cancer
11
HOXD10 2q31.1 HOX4, HOX4D, HOX4E, Hox-4.4 -HOXD10 and Breast Cancer
11
CD68 17p13 GP110, LAMP4, SCARD1 -CD68 and Breast Cancer
11
RBBP8 18q11.2 RIM, COM1, CTIP, JWDS, SAE2, SCKL2 -RBBP8 and Breast Cancer
11
CD74 5q32 II, DHLAG, HLADG, Ia-GAMMA -CD74 and Breast Cancer
11
ADAM12 10q26 MCMP, MLTN, CAR10, MLTNA, MCMPMltna, ADAM12-OT1 -ADAM12 and Breast Cancer
11
CCNE2 8q22.1 CYCE2 -CCNE2 and Breast Cancer
11
PYCARD 16p11.2 ASC, TMS, TMS1, CARD5, TMS-1 -PYCARD and Breast Cancer
11
HDAC2 6q21 HD2, RPD3, YAF1 -HDAC2 and Breast Cancer
11
CYP2C8 10q23.33 CPC8, CYPIIC8, MP-12/MP-20 -CYP2C8 and Breast Cancer
11
PEBP1 12q24.23 PBP, HCNP, PEBP, RKIP, HCNPpp, PEBP-1, HEL-210, HEL-S-34 -PEBP1 and Breast Cancer
11
BMP6 6p24-p23 VGR, VGR1 -BMP6 and Breast Cancer
11
CKAP4 12q23.3 p63, CLIMP-63, ERGIC-63 -CKAP4 and Breast Cancer
10
LCN2 9q34 24p3, MSFI, NGAL -LCN2 and Breast Cancer
10
ADIPOR1 1q32.1 CGI45, PAQR1, ACDCR1, CGI-45, TESBP1A -ADIPOR1 and Breast Cancer
10
HOXA5 7p15.2 HOX1, HOX1C, HOX1.3 -HOXA5 and Breast Cancer
10
SOD1 21q22.11 ALS, SOD, ALS1, IPOA, hSod1, HEL-S-44, homodimer -SOD1 and Breast Cancer
10
NME2 17q21.3 PUF, NDKB, NDPKB, NM23B, NDPK-B, NM23-H2 -NME2 and Breast Cancer
10
KLF5 13q22.1 CKLF, IKLF, BTEB2 -KLF5 and Breast Cancer
10
CDC25B 20p13 -CDC25B and Breast Cancer
10
MED1 17q12 PBP, CRSP1, RB18A, TRIP2, PPARBP, CRSP200, DRIP205, DRIP230, PPARGBP, TRAP220 -MED1 and Breast Cancer
10
ELF3 1q32.2 ERT, ESX, EPR-1, ESE-1 -ELF3 and Breast Cancer
10
MAP2K4 17p12 JNKK, MEK4, MKK4, SEK1, SKK1, JNKK1, SERK1, MAPKK4, PRKMK4, SAPKK1, SAPKK-1 -MAP2K4 and Breast Cancer
10
MARS 12q13.3 MRS, METRS, MTRNS, SPG70 -MARS and Breast Cancer
10
MSN Xq11.1 HEL70 -MSN and Breast Cancer
10
BLM 15q26.1 BS, RECQ2, RECQL2, RECQL3 -BLM and Breast Cancer
10
ST3 11q13-q23 CCTS, TSHL -ST3 and Breast Cancer
10
DHFR 5q11.2-q13.2 DYR, DHFRP1 -DHFR and Breast Cancer
10
HSF1 8q24.3 HSTF1 -HSF1 and Breast Cancer
10
IBSP 4q21.1 BSP, BNSP, SP-II, BSP-II -IBSP and Breast Cancer
10
BMP4 14q22-q23 ZYME, BMP2B, OFC11, BMP2B1, MCOPS6 -BMP4 and Breast Cancer
10
NFIB 9p24.1 CTF, NF1-B, NFI-B, NFIB2, NFIB3, NF-I/B, NFI-RED, HMGIC/NFIB -NFIB and Breast Cancer
10
HMGB1 13q12 HMG1, HMG3, SBP-1 -HMGB1 and Breast Cancer
10
BIK 22q13.31 BP4, NBK, BIP1 -BIK and Breast Cancer
10
TBX3 12q24.21 UMS, XHL, TBX3-ISO -TBX3 and Breast Cancer
10
IRF1 5q31.1 MAR, IRF-1 -IRF1 and Breast Cancer
10
GHRH 20q11.2 GRF, INN, GHRF -GHRH and Breast Cancer
10
ITGB3 17q21.32 GT, CD61, GP3A, BDPLT2, GPIIIa, BDPLT16 -ITGB3 and Breast Cancer
10
FEN1 11q12 MF1, RAD2, FEN-1 -FEN1 and Breast Cancer
10
STMN1 1p36.11 Lag, SMN, OP18, PP17, PP19, PR22, LAP18, C1orf215 -STMN1 and Breast Cancer
10
CCR7 17q12-q21.2 BLR2, EBI1, CCR-7, CD197, CDw197, CMKBR7, CC-CKR-7 -CCR7 and Breast Cancer
10
TBX2 17q23.2 -TBX2 and Breast Cancer
10
KRT19 17q21.2 K19, CK19, K1CS -KRT19 and Breast Cancer
10
ADH1C 4q23 ADH3 -ADH1C and Breast Cancer
10
CDC20 1p34.1 CDC20A, p55CDC, bA276H19.3 -CDC20 and Breast Cancer
9
UGT2B7 4q13 UGT2B9, UDPGTH2, UDPGT2B7, UDPGT 2B9 -UGT2B7 and Breast Cancer
9
PTPN13 4q21.3 PNP1, FAP-1, PTP1E, PTPL1, PTPLE, PTP-BL, hPTP1E, PTP-BAS -PTPN13 and Breast Cancer
9
YES1 18p11.31-p11.21 Yes, c-yes, HsT441, P61-YES -Proto-Oncogene Proteins c-yes and Breast Cancer
9
IL18 11q22.2-q22.3 IGIF, IL-18, IL-1g, IL1F4 -IL18 and Breast Cancer
9
TPD52 8q21.13 D52, N8L, PC-1, PrLZ, hD52 -TPD52 and Breast Cancer
9
ANGPT2 8p23.1 ANG2, AGPT2 -ANGPT2 and Breast Cancer
9
TLR9 3p21.3 CD289 -TLR9 and Breast Cancer
9
TP73 1p36.3 P73 -TP73 and Breast Cancer
9
COPS5 8q13.1 CSN5, JAB1, SGN5, MOV-34 -COPS5 and Breast Cancer
9
HAS2 8q24.12 -HAS2 and Breast Cancer
9
MAPK8 10q11.22 JNK, JNK1, PRKM8, SAPK1, JNK-46, JNK1A2, SAPK1c, JNK21B1/2 -MAPK8 and Breast Cancer
9
CRP 1q23.2 PTX1 -CRP and Breast Cancer
9
ATG5 6q21 ASP, APG5, APG5L, hAPG5, APG5-LIKE -ATG5 and Breast Cancer
9
NFKB2 10q24 p52, p100, H2TF1, LYT10, CVID10, LYT-10, NF-kB2 -NFKB2 and Breast Cancer
9
PMAIP1 18q21.32 APR, NOXA -PMAIP1 and Breast Cancer
9
TCF3 19p13.3 E2A, E47, ITF1, VDIR, TCF-3, bHLHb21 -TCF3 and Breast Cancer
9
FURIN 15q26.1 FUR, PACE, SPC1, PCSK3 -FURIN and Breast Cancer
9
CUL4A 13q34 -CUL4A and Breast Cancer
9
RARS 5q35.1 ArgRS, DALRD1 -RARS and Breast Cancer
9
WARS 14q32.31 IFI53, IFP53, GAMMA-2 -WARS and Breast Cancer
9
COL1A1 17q21.33 OI4 -COL1A1 and Breast Cancer
9
CEBPD 8p11.2-p11.1 CELF, CRP3, C/EBP-delta, NF-IL6-beta -CEBPD and Breast Cancer
9
MUTYH 1p34.1 MYH -MUTYH and Breast Cancer
9
PER2 2q37.3 FASPS, FASPS1 -PER2 and Breast Cancer
9
PSEN2 1q42.13 AD4, PS2, AD3L, STM2, CMD1V -PSEN2 and Breast Cancer
9
RAF1 3p25 NS5, CRAF, Raf-1, c-Raf, CMD1NN -RAF1 and Breast Cancer
9
BCAR3 1p22.1 NSP2, SH2D3B -BCAR3 and Breast Cancer
9
SDC1 2p24.1 SDC, CD138, SYND1, syndecan -SDC1 and Breast Cancer
9
IGFBP2 2q35 IBP2, IGF-BP53 -IGFBP2 and Breast Cancer
9
WEE1 11p15.4 WEE1A, WEE1hu -WEE1 and Breast Cancer
9
CCNB2 15q22.2 HsT17299 -CCNB2 and Breast Cancer
9
TGFB3 14q24 ARVD, RNHF, ARVD1, TGF-beta3 -TGFB3 and Breast Cancer
9
CASP1 11q23 ICE, P45, IL1BC -CASP1 and Breast Cancer
8
MDC1 6p21.3 NFBD1 -MDC1 and Breast Cancer
8
LIG4 13q33-q34 LIG4S -LIG4 and Breast Cancer
8
CDH3 16q22.1 CDHP, HJMD, PCAD -CDH3 and Breast Cancer
8
INSR 19p13.3-p13.2 HHF5, CD220 -INSR and Breast Cancer
8
B2M 15q21-q22.2 -B2M and Breast Cancer
8
EFNB2 13q33 HTKL, EPLG5, Htk-L, LERK5 -EFNB2 expression in Breast Cancer
8
CCR5 3p21.31 CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22, CC-CKR-5 -CCR5 and Breast Cancer
8
SUZ12 17q11.2 CHET9, JJAZ1 -SUZ12 and Breast Cancer
8
AKR1C2 10p15-p14 DD, DD2, TDD, BABP, DD-2, DDH2, HBAB, HAKRD, MCDR2, SRXY8, DD/BABP, AKR1C-pseudo -AKR1C2 and Breast Cancer
8
NR5A2 1q32.1 B1F, CPF, FTF, B1F2, LRH1, LRH-1, FTZ-F1, hB1F-2, FTZ-F1beta -NR5A2 and Breast Cancer
8
SKP1 5q31 OCP2, p19A, EMC19, SKP1A, OCP-II, TCEB1L -SKP1 and Breast Cancer
8
POT1 7q31.33 CMM10, HPOT1 -POT1 and Breast Cancer
8
IL17A 6p12 IL17, CTLA8, IL-17, IL-17A -IL17A and Breast Cancer
8
CLDN4 7q11.23 CPER, CPE-R, CPETR, CPETR1, WBSCR8, hCPE-R -CLDN4 and Breast Cancer
8
ERCC5 13q33 XPG, UVDR, XPGC, COFS3, ERCM2, ERCC5-201 -ERCC5 and Breast Cancer
8
BUB3 10q26 BUB3L, hBUB3 -BUB3 and Breast Cancer
8
BMP7 20q13 OP-1 -BMP7 and Breast Cancer
8
XIST Xq13.2 SXI1, swd66, DXS1089, DXS399E, LINC00001, NCRNA00001 -XIST and Breast Cancer
8
PLAU 10q22.2 ATF, QPD, UPA, URK, u-PA, BDPLT5 -PLAU and Breast Cancer
8
BNIP3L 8p21 NIX, BNIP3a -BNIP3L and Breast Cancer
8
KLK14 19q13.3-q13.4 KLK-L6 -KLK14 and Breast Cancer
8
L1CAM Xq28 S10, HSAS, MASA, MIC5, SPG1, CAML1, CD171, HSAS1, N-CAML1, NCAM-L1, N-CAM-L1 -L1CAM and Breast Cancer
8
SUV39H1 Xp11.23 MG44, KMT1A, SUV39H, H3-K9-HMTase 1 -SUV39H1 and Breast Cancer
8
IL17C 16q24 CX2, IL-17C -IL17C and Breast Cancer
8
POSTN 13q13.3 PN, OSF2, OSF-2, PDLPOSTN, periostin -POSTN and Breast Cancer
8
SOCS3 17q25.3 CIS3, SSI3, ATOD4, Cish3, SSI-3, SOCS-3 -SOCS3 and Breast Cancer
8
CBFA2T3 16q24 ETO2, MTG16, MTGR2, ZMYND4 -CBFA2T3 and Breast Cancer
8
ARID1A 1p35.3 ELD, B120, OSA1, P270, hELD, BM029, MRD14, hOSA1, BAF250, C1orf4, BAF250a, SMARCF1 -ARID1A and Breast Cancer
8
CASP10 2q33-q34 MCH4, ALPS2, FLICE2 -CASP10 and Breast Cancer
8
ATG7 3p25.3 GSA7, APG7L, APG7-LIKE -ATG7 and Breast Cancer
8
EPHB6 7q33-q35 HEP -EPHB6 and Breast Cancer
8
WNT10B 12q13 SHFM6, WNT-12 -WNT10B and Breast Cancer
8
DDB2 11p12-p11 DDBB, UV-DDB2 -DDB2 and Breast Cancer
8
SUMO1 2q33 DAP1, GMP1, PIC1, SMT3, UBL1, OFC10, SENP2, SMT3C, SMT3H3 -SUMO1 and Breast Cancer
8
RHOBTB2 8p21.3 DBC2 -RHOBTB2 and Breast Cancer
8
FCGR3A 1q23 CD16, FCG3, CD16A, FCGR3, IGFR3, IMD20, FCR-10, FCRIII, FCGRIII, FCRIIIA -FCGR3A and Breast Cancer
8
CSF1 1p13.3 MCSF, CSF-1 -CSF1 and Breast Cancer
8
TEP1 14q11.2 TP1, TLP1, p240, TROVE1, VAULT2 -TEP1 and Breast Cancer
8
IL1B 2q14 IL-1, IL1F2, IL1-BETA -IL1B and Breast Cancer
8
WIF1 12q14.3 WIF-1 -WIF1 and Breast Cancer
8
ADRB2 5q31-q32 BAR, B2AR, ADRBR, ADRB2R, BETA2AR -ADRB2 and Breast Cancer
8
FGF8 10q24 HH6, AIGF, KAL6, FGF-8, HBGF-8 -FGF8 and Breast Cancer
8
TES 7q31.2 TESS, TESS-2 -TES and Breast Cancer
8
MSX2 5q35.2 FPP, MSH, PFM, CRS2, HOX8, PFM1 -MSX2 and Breast Cancer
8
CIC 19q13.2 -CIC and Breast Cancer
8
BMP2 20p12 BDA2, BMP2A -BMP2 and Breast Cancer
8
ANXA1 9q21.13 ANX1, LPC1 -ANXA1 and Breast Cancer
8
BIN1 2q14 AMPH2, AMPHL, SH3P9 -BIN1 and Breast Cancer
8
KLK6 19q13.3 hK6, Bssp, Klk7, SP59, PRSS9, PRSS18 -KLK6 and Breast Cancer
8
E2F2 1p36 E2F-2 -E2F2 and Breast Cancer
8
SOX4 6p22.3 EVI16 -SOX4 and Breast Cancer
8
DDX5 17q21 p68, HLR1, G17P1, HUMP68 -DDX5 and Breast Cancer
8
ABCC2 10q24 DJS, MRP2, cMRP, ABC30, CMOAT -ABCC2 and Breast Cancer
8
TRA 14q11.2 IMD7, TCRA, TCRD, TRA@, TRAC -TRA and Breast Cancer
8
KDM5B 1q32.1 CT31, PLU1, PUT1, PLU-1, JARID1B, PPP1R98, RBBP2H1A -KDM5B and Breast Cancer
8
MALL 2q13 BENE -MALL and Breast Cancer
8
WNT3A 1q42 -WNT3A and Breast Cancer
8
BUB1B 15q15 MVA1, SSK1, BUBR1, Bub1A, MAD3L, hBUBR1, BUB1beta -BUB1B and Breast Cancer
8
RAB25 1q22 CATX-8, RAB11C -RAB25 and Breast Cancer
8
GPC3 Xq26.1 SGB, DGSX, MXR7, SDYS, SGBS, OCI-5, SGBS1, GTR2-2 -GPC3 and Breast Cancer
8
TRAF2 9q34 TRAP, TRAP3, MGC:45012 -TRAF2 and Breast Cancer
7
ATF4 22q13.1 CREB2, TXREB, CREB-2, TAXREB67 -ATF4 and Breast Cancer
7
CDH2 18q11.2 CDHN, NCAD, CD325, CDw325 -CDH2 and Breast Cancer
7
MYOD1 11p15.4 PUM, MYF3, MYOD, bHLHc1 -MYOD1 and Breast Cancer
7
LIF 22q12.2 CDF, DIA, HILDA, MLPLI -LIF and Breast Cancer
7
NAV1 1q32.3 POMFIL3, UNC53H1, STEERIN1 -NAV1 and Breast Cancer
7
ADAM17 2p25 CSVP, TACE, NISBD, ADAM18, CD156B, NISBD1 -ADAM17 and Breast Cancer
7
CXCL13 4q21 BLC, BCA1, ANGIE, BCA-1, BLR1L, ANGIE2, SCYB13 -CXCL13 and Breast Cancer
7
EPHB4 7q22 HTK, MYK1, TYRO11 -EPHB4 and Breast Cancer
7
KEAP1 19p13.2 INrf2, KLHL19 -KEAP1 and Breast Cancer
7
MAP2K2 19p13.3 CFC4, MEK2, MKK2, MAPKK2, PRKMK2 -MAP2K2 and Breast Cancer
7
GSTM3 1p13.3 GST5, GSTB, GTM3, GSTM3-3 -GSTM3 and Breast Cancer
7
DKK3 11p15.2 RIG, REIC -DKK3 and Breast Cancer
7
TNFSF15 9q32 TL1, TL1A, VEGI, VEGI192A -TNFSF15 and Breast Cancer
7
NEFL 8p21 NFL, NF-L, NF68, CMT1F, CMT2E, PPP1R110 -NEFL and Breast Cancer
7
PRINS 10p12.1 NCRNA00074 -PRINS and Breast Cancer
7
E2F5 8q21.2 E2F-5 -E2F5 and Breast Cancer
7
YY1AP1 1q22 YAP, HCCA1, HCCA2, YY1AP -YY1AP1 and Breast Cancer
7
NCOA2 8q13.3 SRC2, TIF2, GRIP1, KAT13C, NCoA-2, bHLHe75 -NCOA2 and Breast Cancer
7
UHRF1 19p13.3 Np95, hNP95, ICBP90, RNF106, hUHRF1, huNp95 -UHRF1 and Breast Cancer
7
NDRG1 8q24.3 GC4, RTP, DRG1, NDR1, NMSL, TDD5, CAP43, CMT4D, DRG-1, HMSNL, RIT42, TARG1, PROXY1 -NDRG1 and Breast Cancer
7
RPA1 17p13.3 HSSB, RF-A, RP-A, REPA1, RPA70, MST075 -RPA1 and Breast Cancer
7
S100P 4p16 MIG9 -S100P and Breast Cancer
7
PON1 7q21.3 ESA, PON, MVCD5 -PON1 and Breast Cancer
7
HBEGF 5q23 DTR, DTS, DTSF, HEGFL -HBEGF and Breast Cancer
7
BRD4 19p13.1 CAP, MCAP, HUNK1, HUNKI -BRD4 and Breast Cancer
7
RICTOR 5p13.1 PIA, AVO3, hAVO3 -RICTOR and Breast Cancer
7
IKBKE 1q32.1 IKKE, IKKI, IKK-E, IKK-i -IKBKE and Breast Cancer
7
ALDH3A1 17p11.2 ALDH3, ALDHIII -ALDH3A1 and Breast Cancer
7
TFPI 2q32 EPI, TFI, LACI, TFPI1 -TFPI and Breast Cancer
7
KPNA2 17q24.2 QIP2, RCH1, IPOA1, SRP1alpha -KPNA2 and Breast Cancer
7
PAEP 9q34 GD, GdA, GdF, GdS, PEP, PAEG, PP14 -PAEP and Breast Cancer
7
YWHAZ 8q23.1 HEL4, YWHAD, KCIP-1, HEL-S-3, 14-3-3-zeta -YWHAZ and Breast Cancer
7
ADAM9 8p11.22 MCMP, MDC9, CORD9, Mltng -ADAM9 and Breast Cancer
7
DUSP1 5q34 HVH1, MKP1, CL100, MKP-1, PTPN10 -DUSP1 and Breast Cancer
7
GATA4 8p23.1-p22 TOF, ASD2, VSD1, TACHD -GATA4 and Breast Cancer
7
CDC6 17q21.3 CDC18L, HsCDC6, HsCDC18 -CDC6 and Breast Cancer
7
HOXA1 7p15.3 BSAS, HOX1, HOX1F -HOXA1 and Breast Cancer
7
GAB2 11q14.1 -GAB2 and Breast Cancer
7
TJP1 15q13 ZO-1 -TJP1 and Breast Cancer
7
ATF3 1q32.3 -ATF3 and Breast Cancer
7
BMPR2 2q33-q34 BMR2, PPH1, BMPR3, BRK-3, POVD1, T-ALK, BMPR-II -BMPR2 and Breast Cancer
7
KRT18 12q13 K18, CYK18 -KRT18 and Breast Cancer
7
FOXC2 16q24.1 LD, MFH1, MFH-1, FKHL14 -FOXC2 and Breast Cancer
7
XBP1 22q12.1 XBP2, TREB5, XBP-1 -XBP1 and Breast Cancer
7
TLR3 4q35 CD283, IIAE2 -TLR3 and Breast Cancer
7
IQGAP1 15q26.1 SAR1, p195, HUMORFA01 -IQGAP1 and Breast Cancer
7
CTSD 11p15.5 CPSD, CLN10, HEL-S-130P -CTSD and Breast Cancer
7
KDM1A 1p36.12 AOF2, KDM1, LSD1, BHC110 -KDM1A and Breast Cancer
7
S100A8 1q21 P8, MIF, NIF, CAGA, CFAG, CGLA, L1Ag, MRP8, CP-10, MA387, 60B8AG -S100A8 and Breast Cancer
7
TERF2 16q22.1 TRF2, TRBF2 -TERF2 and Breast Cancer
7
PTPRQ 12q21.2 DFNB84, DFNB84A, PTPGMC1, R-PTP-Q -PTPRQ and Breast Cancer
7
MAML1 5q35 Mam1, Mam-1 -MAML1 and Breast Cancer
7
ADIPOR2 12p13.31 PAQR2, ACDCR2 -ADIPOR2 and Breast Cancer
7
SREBF1 17p11.2 SREBP1, bHLHd1, SREBP-1c -SREBF1 and Breast Cancer
7
PTPRH 19q13.4 SAP1, R-PTP-H -PTPRH and Breast Cancer
7
NR4A1 12q13 HMR, N10, TR3, NP10, GFRP1, NAK-1, NGFIB, NUR77 -NR4A1 and Breast Cancer
7
PTPRT 20q12-q13 RPTPrho -PTPRT and Breast Cancer
7
ZFP36 19q13.1 TTP, G0S24, GOS24, TIS11, NUP475, zfp-36, RNF162A -ZFP36 and Breast Cancer
7
LATS1 6q25.1 wts, WARTS -LATS1 and Breast Cancer
7
NQO2 6p25.2 QR2, DHQV, DIA6, NMOR2 -NQO2 and Breast Cancer
7
PCGF2 17q12 MEL-18, RNF110, ZNF144 -PCGF2 and Breast Cancer
7
ATF2 2q32 HB16, CREB2, TREB7, CREB-2, CRE-BP1 -ATF2 and Breast Cancer
7
AGO2 8q24 Q10, EIF2C2 -EIF2C2 and Breast Cancer
7
S100A9 1q21 MIF, NIF, P14, CAGB, CFAG, CGLB, L1AG, LIAG, MRP14, 60B8AG, MAC387 -S100A9 and Breast Cancer
7
CUL1 7q36.1 -CUL1 and Breast Cancer
7
CXCL10 4q21 C7, IFI10, INP10, IP-10, crg-2, mob-1, SCYB10, gIP-10 -CXCL10 and Breast Cancer
7
NEDD4 15q RPF1, NEDD4-1 -NEDD4 and Breast Cancer
7
EPOR 19p13.3-p13.2 EPO-R -EPOR and Breast Cancer
7
ITGA4 2q31.3 IA4, CD49D -ITGA4 and Breast Cancer
6
PLAT 8p12 TPA, T-PA -PLAT and Breast Cancer
6
ADAM10 15q22 RAK, kuz, AD10, AD18, MADM, CD156c, HsT18717 -ADAM10 and Breast Cancer
6
TANK 2q24-q31 ITRAF, TRAF2, I-TRAF -TANK and Breast Cancer
6
IL6ST 5q11.2 CD130, GP130, CDW130, IL-6RB -IL6ST and Breast Cancer
6
CMBL 5p15.2 JS-1 -CMBL and Breast Cancer
6
WNT2 7q31.2 IRP, INT1L1 -WNT2 and Breast Cancer
6
CYP11A1 15q23-q24 CYP11A, CYPXIA1, P450SCC -CYP11A1 and Breast Cancer
6
NUMB 14q24.3 S171, C14orf41, c14_5527 -NUMB and Breast Cancer
6
MCM2 3q21 BM28, CCNL1, CDCL1, cdc19, D3S3194, MITOTIN -MCM2 and Breast Cancer
6
LGALS1 22q13.1 GBP, GAL1 -LGALS1 and Breast Cancer
6
CD46 1q32 MCP, TLX, AHUS2, MIC10, TRA2.10 -CD46 and Breast Cancer
6
SQSTM1 5q35 p60, p62, A170, OSIL, PDB3, ZIP3, p62B -SQSTM1 and Breast Cancer
6
CHEK1 11q24.2 CHK1 -CHEK1 and Breast Cancer
6
ABCC5 3q27 MRP5, SMRP, ABC33, MOATC, MOAT-C, pABC11, EST277145 -ABCC5 and Breast Cancer
6
ROBO1 3p12 SAX3, DUTT1 -ROBO1 and Breast Cancer
6
MMP8 11q22.3 HNC, CLG1, MMP-8, PMNL-CL -MMP8 and Breast Cancer
6
AKR1C1 10p15-p14 C9, DD1, DDH, DDH1, H-37, HBAB, MBAB, HAKRC, DD1/DD2, 2-ALPHA-HSD, 20-ALPHA-HSD -AKR1C1 and Breast Cancer
6
RAC3 17q25.3 -RAC3 and Breast Cancer
6
SOCS2 12q CIS2, SSI2, Cish2, SSI-2, SOCS-2, STATI2 -SOCS2 and Breast Cancer
6
YAP1 11q13 YAP, YKI, COB1, YAP2, YAP65 -YAP1 and Breast Cancer
6
LYVE1 11p15 HAR, XLKD1, LYVE-1, CRSBP-1 -LYVE1 and Breast Cancer
6
ABCC3 17q22 MLP2, MRP3, ABC31, MOAT-D, cMOAT2, EST90757 -ABCC3 and Breast Cancer
6
NOD2 16q21 CD, ACUG, BLAU, IBD1, NLRC2, NOD2B, CARD15, CLR16.3, PSORAS1 -NOD2 and Breast Cancer
6
IL4 5q31.1 BSF1, IL-4, BCGF1, BSF-1, BCGF-1 -IL4 and Breast Cancer
6
HMMR 5q34 CD168, IHABP, RHAMM -HMMR and Breast Cancer
6
PDPK1 16p13.3 PDK1, PDPK2, PDPK2P, PRO0461 -PDPK1 and Breast Cancer
6
HOXA10 7p15.2 PL, HOX1, HOX1H, HOX1.8 -HOXA10 and Breast Cancer
6
PTPN1 20q13.1-q13.2 PTP1B -PTPN1 and Breast Cancer
6
HOTAIR 12q13.13 HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072 -HOTAIR and Breast Cancer
6
SLIT2 4p15.2 SLIL3, Slit-2 -SLIT2 and Breast Cancer
6
MTA2 11q12-q13.1 PID, MTA1L1 -MTA2 and Breast Cancer
6
KL 13q12 -KL and Breast Cancer
6
PYGM 11q12-q13.2 -PYGM and Breast Cancer
6
KRT8 12q13 K8, KO, CK8, CK-8, CYK8, K2C8, CARD2 -KRT8 and Breast Cancer
6
LOXL2 8p21.3 LOR2, WS9-14 -LOXL2 and Breast Cancer
6
HNRNPA2B1 7p15 RNPA2, HNRPA2, HNRPB1, SNRPB1, HNRNPA2, HNRNPB1, IBMPFD2, HNRPA2B1 -HNRNPA2B1 and Breast Cancer
6
KLK5 19q13.33 SCTE, KLKL2, KLK-L2 -KLK5 and Breast Cancer
6
NBR1 17q21.31 IAI3B, M17S2, MIG19, 1A1-3B -NBR1 and Breast Cancer
6
PMP22 17p12 DSS, HNPP, CMT1A, CMT1E, GAS-3, Sp110, HMSNIA -PMP22 and Breast Cancer
6
WISP1 8q24.22 CCN4, WISP1c, WISP1i, WISP1tc -WISP1 and Breast Cancer
6
DMBT1 10q26.13 GP340, muclin -DMBT1 and Breast Cancer
6
DDR1 6p21.3 CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, CD167, EDDR1, MCK10, NTRK4, PTK3A -DDR1 and Breast Cancer
6
LTA 6p21.3 LT, TNFB, TNFSF1 -LTA and Breast Cancer
6
ST7 7q31.2 HELG, RAY1, SEN4, TSG7, ETS7q, FAM4A, FAM4A1 -ST7 and Breast Cancer
6
DACH1 13q22 DACH -DACH1 and Breast Cancer
6
PTPRG 3p21-p14 PTPG, HPTPG, RPTPG, R-PTP-GAMMA -PTPRG and Breast Cancer
6
NEDD9 6p25-p24 CAS2, CASL, HEF1, CAS-L, CASS2 -NEDD9 and Breast Cancer
6
STC1 8p21-p11.2 STC -STC1 and Breast Cancer
6
FGF7 15q21.2 KGF, HBGF-7 -FGF7 and Breast Cancer
6
BCAS1 20q13.2 AIBC1, NABC1 -BCAS1 and Breast Cancer
6
STAT6 12q13 STAT6B, STAT6C, D12S1644, IL-4-STAT -STAT6 and Breast Cancer
6
KISS1R 19p13.3 HH8, CPPB1, GPR54, AXOR12, KISS-1R, HOT7T175 -KISS1R and Breast Cancer
6
ETV6 12p13 TEL, TEL/ABL Translocation
-t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
6
ARL11 13q14.2 ARLTS1 -ARL11 and Breast Cancer
6
EEF1A2 20q13.3 HS1, STN, EF1A, STNL, EEF1AL, EF-1-alpha-2 -EEF1A2 and Breast Cancer
6
TACR1 2p12 SPR, NK1R, NKIR, TAC1R -TACR1 and Breast Cancer
6
IL1A 2q14 IL1, IL-1A, IL1F1, IL1-ALPHA -IL1A and Breast Cancer
6
WHSC1L1 8p11.2 NSD3, pp14328 -WHSC1L1 and Breast Cancer
6
PRDM2 1p36.21 RIZ, KMT8, RIZ1, RIZ2, MTB-ZF, HUMHOXY1 -PRDM2 and Breast Cancer
6
GDNF 5p13.1-p12 ATF1, ATF2, HSCR3, HFB1-GDNF -GDNF and Breast Cancer
6
ADH1B 4q23 ADH2, HEL-S-117 -ADH1B and Breast Cancer
6
MIF 22q11.23 GIF, GLIF, MMIF -MIF and Breast Cancer
6
PIK3R1 5q13.1 p85, AGM7, GRB1, IMD36, p85-ALPHA -PIK3R1 and Breast Cancer
6
CUL3 2q36.2 CUL-3, PHA2E -CUL3 and Breast Cancer
6
AXL 19q13.1 ARK, UFO, JTK11, Tyro7 -AXL and Breast Cancer
6
CHUK 10q24-q25 IKK1, IKKA, IKBKA, TCF16, NFKBIKA, IKK-alpha -CHUK and Breast Cancer
6
TNKS 8p23.1 TIN1, ARTD5, PARPL, TINF1, TNKS1, pART5, PARP5A, PARP-5a -TNKS and Breast Cancer
6
CA12 15q22 CAXII, HsT18816 -CA12 and Breast Cancer
6
TNFRSF10C 8p22-p21 LIT, DCR1, TRID, CD263, TRAILR3, TRAIL-R3, DCR1-TNFR -TNFRSF10C and Breast Cancer
6
EBAG9 8q23 EB9, PDAF -EBAG9 and Breast Cancer
6
HDAC4 2q37.3 HD4, AHO3, BDMR, HDACA, HA6116, HDAC-4, HDAC-A -HDAC4 and Breast Cancer
6
SOX17 8q11.23 VUR3 -SOX17 and Breast Cancer
5
BIRC3 11q22 AIP1, API2, MIHC, CIAP2, HAIP1, HIAP1, MALT2, RNF49, c-IAP2 -BIRC3 and Breast Cancer
5
CXCR1 2q35 C-C, CD128, CD181, CKR-1, IL8R1, IL8RA, CMKAR1, IL8RBA, CDw128a, C-C-CKR-1 -CXCR1 and Breast Cancer
5
SEMA3B 3p21.3 SemA, SEMA5, SEMAA, semaV, LUCA-1 -SEMA3B and Breast Cancer
5
S100A2 1q21 CAN19, S100L -S100A2 and Breast Cancer
5
LASP1 17q11-q21.3 MLN50, Lasp-1 -LASP1 and Breast Cancer
5
CEACAM6 19q13.2 NCA, CEAL, CD66c -CEACAM6 and Breast Cancer
5
TLR1 4p14 TIL, CD281, rsc786, TIL. LPRS5 -TLR1 and Breast Cancer
5
IGFBP7 4q12 AGM, PSF, TAF, FSTL2, IBP-7, MAC25, IGFBP-7, RAMSVPS, IGFBP-7v, IGFBPRP1 -IGFBP7 and Breast Cancer
5
SKI 1p36.33 SGS, SKV -SKI and Breast Cancer
5
ISG15 1p36.33 G1P2, IP17, UCRP, IFI15, hUCRP -ISG15 and Breast Cancer
5
CDK7 5q12.1 CAK1, HCAK, MO15, STK1, CDKN7, p39MO15 -CDK7 and Breast Cancer
5
ANGPTL4 19p13.3 NL2, ARP4, FIAF, HARP, PGAR, HFARP, TGQTL, UNQ171, pp1158, ANGPTL2 -ANGPTL4 and Breast Cancer
5
CXCL14 5q31 KEC, KS1, BMAC, BRAK, NJAC, MIP2G, MIP-2g, SCYB14 -CXCL14 and Breast Cancer
5
TPX2 20q11.2 DIL2, p100, DIL-2, HCTP4, FLS353, HCA519, REPP86, C20orf1, C20orf2, GD:C20orf1 -TPX2 and Breast Cancer
5
TLR2 4q32 TIL4, CD282 -TLR2 and Breast Cancer
5
FHL2 2q12.2 DRAL, AAG11, FHL-2, SLIM3, SLIM-3 -FHL2 and Breast Cancer
5
APOB 2p24-p23 FLDB, LDLCQ4 -APOB and Breast Cancer
5
TXNIP 1q21.1 THIF, VDUP1, HHCPA78, EST01027 -TXNIP and Breast Cancer
5
NUMA1 11q13 NUMA, NMP-22 -NUMA1 and Breast Cancer
5
CCL21 9p13 ECL, SLC, CKb9, TCA4, 6Ckine, SCYA21 -CCL21 and Breast Cancer
5
TGFBR3 1p33-p32 BGCAN, betaglycan -TGFBR3 and Breast Cancer
5
MVP 16p11.2 LRP, VAULT1 -MVP and Breast Cancer
5
WNT4 1p36.23-p35.1 WNT-4, SERKAL -WNT4 and Breast Cancer
5
DKC1 Xq28 DKC, CBF5, DKCX, NAP57, NOLA4, XAP101 -DKC1 and Breast Cancer
5
CLDN7 17p13.1 CLDN-7, CEPTRL2, CPETRL2, Hs.84359, claudin-1 -CLDN7 and Breast Cancer
5
RAG2 11p13 RAG-2 -RAG2 and Breast Cancer
5
SIN3A 15q24.2 -SIN3A and Breast Cancer
5
MAGEA4 Xq28 CT1.4, MAGE4, MAGE4A, MAGE4B, MAGE-41, MAGE-X2 -MAGEA4 and Breast Cancer
5
ING4 12p13.31 my036, p29ING4 -ING4 and Breast Cancer
5
AMFR 16q21 GP78, RNF45 -AMFR and Breast Cancer
5
FGF10 5p13-p12 -FGF10 and Breast Cancer
5
CCNA1 13q12.3-q13 CT146 -CCNA1 and Breast Cancer
5
XRCC6 22q13.2 ML8, KU70, TLAA, CTC75, CTCBF, G22P1 -XRCC6 and Breast Cancer
5
POU1F1 3p11 PIT1, CPHD1, GHF-1, Pit-1, POU1F1a -POU1F1 and Breast Cancer
5
CKS1B 1q21.2 CKS1, ckshs1, PNAS-16, PNAS-18 -CKS1B and Breast Cancer
5
ACTA2 10q23.3 AAT6, ACTSA, MYMY5 -ACTA2 and Breast Cancer
5
NGFR 17q21-q22 CD271, p75NTR, TNFRSF16, p75(NTR), Gp80-LNGFR -NGFR and Breast Cancer
5
CALU 7q32.1 -CALU and Breast Cancer
5
FRZB 2q32.1 FRE, OS1, FZRB, hFIZ, FRITZ, FRP-3, FRZB1, SFRP3, SRFP3, FRZB-1, FRZB-PEN -FRZB and Breast Cancer
5
CYBA 16q24 p22-PHOX -CYBA and Breast Cancer
5
DRD2 11q23 D2R, D2DR -DRD2 and Breast Cancer
5
SIRT3 11p15.5 SIR2L3 -SIRT3 and Breast Cancer
5
DDIT4 10q22.1 Dig2, REDD1, REDD-1 -DDIT4 and Breast Cancer
5
SAT2 17p13.1 SSAT2 -SAT2 and Breast Cancer
5
MAD1L1 7p22 MAD1, PIG9, TP53I9, TXBP181 -MAD1L1 and Breast Cancer
5
FOSB 19q13.32 AP-1, G0S3, GOS3, GOSB -FOSB and Breast Cancer
5
LRP6 12p13.2 ADCAD2 -LRP6 and Breast Cancer
5
GNRHR 4q21.2 HH7, GRHR, LRHR, LHRHR, GNRHR1 -GNRHR and Breast Cancer
5
TXNRD1 12q23-q24.1 TR, TR1, TXNR, TRXR1, GRIM-12 -TXNRD1 and Breast Cancer
5
TAGLN 11q23.2 SM22, SMCC, TAGLN1, WS3-10 -TAGLN and Breast Cancer
5
CRY2 11p11.2 HCRY2, PHLL2 -CRY2 and Breast Cancer
5
MTHFD1 14q24 MTHFC, MTHFD -MTHFD1 and Breast Cancer
5
SULF2 20q12-q13.2 HSULF-2 -SULF2 and Breast Cancer
5
PER3 1p36.23 GIG13 -PER3 and Breast Cancer
5
POLD1 19q13.3 CDC2, MDPL, POLD, CRCS10 -POLD1 and Breast Cancer
5
TNFAIP3 6q23 A20, OTUD7C, TNFA1P2 -TNFAIP3 and Breast Cancer
5
PER1 17p13.1 PER, hPER, RIGUI -PER1 and Breast Cancer
5
PTPRF 1p34 LAR, BNAH2 -PTPRF and Breast Cancer
5
CTBP1 4p16 BARS -CTBP1 and Breast Cancer
5
FOSL1 11q13 FRA, FRA1, fra-1 -FOSL1 and Breast Cancer
5
CCR2 3p21.31 CKR2, CCR-2, CCR2A, CCR2B, CD192, CKR2A, CKR2B, CMKBR2, MCP-1-R, CC-CKR-2 -CCR2 and Breast Cancer
5
CCNG2 4q21.1 -CCNG2 and Breast Cancer
5
ALOX5 10q11.2 5-LO, 5LPG, LOG5, 5-LOX -ALOX5 and Breast Cancer
5
EREG 4q13.3 ER -EREG and Breast Cancer
5
SHMT1 17p11.2 SHMT, CSHMT -SHMT1 and Breast Cancer
5
UGT2B15 4q13 HLUG4, UGT2B8, UDPGTH3, UDPGT 2B8, UDPGT2B15 -UGT2B15 and Breast Cancer
5
GSTO2 10q25.1 GSTO 2-2, bA127L20.1 -GSTO2 and Breast Cancer
5
PPP2R1B 11q23.2 PR65B, PP2A-Abeta -PPP2R1B and Breast Cancer
5
TPD52L1 6q22-q23 D53, hD53 -TPD52L1 and Breast Cancer
5
REST 4q12 XBR, NRSF -REST and Breast Cancer
5
CASP4 11q22.2-q22.3 TX, ICH-2, Mih1/TX, ICEREL-II, ICE(rel)II -CASP4 and Breast Cancer
5
ADIPOQ 3q27 ACDC, ADPN, APM1, APM-1, GBP28, ACRP30, ADIPQTL1 -ADIPOQ and Breast Cancer
5
PGK1 Xq13.3 PGKA, MIG10, HEL-S-68p -PGK1 and Breast Cancer
5
TUBB3 16q24.3 CDCBM, FEOM3, TUBB4, CDCBM1, CFEOM3, beta-4, CFEOM3A -TUBB3 and Breast Cancer
5
PTPRJ 11p11.2 DEP1, SCC1, CD148, HPTPeta, R-PTP-ETA -PTPRJ and Breast Cancer
5
MIR107 10q23.31 MIRN107, miR-107 -MicroRNA mir-107 and Breast Cancer
5
SCRIB 8q24.3 CRIB1, SCRB1, SCRIB1, Vartul -SCRIB and Breast Cancer
5
ARNTL 11p15 TIC, JAP3, MOP3, BMAL1, PASD3, BMAL1c, bHLHe5 -ARNTL and Breast Cancer
5
HIPK2 7q32-q34 PRO0593 -HIPK2 and Breast Cancer
5
IER3 6p21.3 DIF2, IEX1, PRG1, DIF-2, GLY96, IEX-1, IEX-1L -IER3 and Breast Cancer
5
TRIO 5p15.2 tgat, ARHGEF23 -TRIO and Breast Cancer
5
EGLN1 1q42.1 HPH2, PHD2, SM20, ECYT3, HPH-2, HIFPH2, ZMYND6, C1orf12, HIF-PH2 -EGLN1 and Breast Cancer
5
GSTO1 10q25.1 P28, SPG-R, GSTO 1-1, GSTTLp28, HEL-S-21 -GSTO1 and Breast Cancer
5
CXCR2 2q35 CD182, IL8R2, IL8RA, IL8RB, CMKAR2, CDw128b -CXCR2 and Breast Cancer
5
CD36 7q11.2 FAT, GP4, GP3B, GPIV, CHDS7, PASIV, SCARB3, BDPLT10 -CD36 and Breast Cancer
5
LARS 5q32 LRS, LEUS, LFIS, ILFS1, LARS1, LEURS, PIG44, RNTLS, HSPC192, hr025Cl -LARS and Breast Cancer
5
PRC1 15q26.1 ASE1 -PRC1 and Breast Cancer
5
HSPA8 11q24.1 LAP1, HSC54, HSC70, HSC71, HSP71, HSP73, LAP-1, NIP71, HEL-33, HSPA10, HEL-S-72p -HSPA8 and Breast Cancer
5
KLK4 19q13.41 ARM1, EMSP, PSTS, AI2A1, EMSP1, KLK-L1, PRSS17, kallikrein -KLK4 and Breast Cancer
5
SLC19A2 1q23.3 TC1, THT1, TRMA, THMD1, THTR1 -SLC19A2 and Breast Cancer
5
SULF1 8q13.2 SULF-1, HSULF-1 -SULF1 and Breast Cancer
5
USF1 1q22-q23 UEF, FCHL, MLTF, FCHL1, MLTFI, HYPLIP1, bHLHb11 -USF1 and Breast Cancer
5
TPM1 15q22.1 CMH3, TMSA, CMD1Y, LVNC9, C15orf13, HTM-alpha -TPM1 and Breast Cancer
5
BMPR1B 4q22-q24 ALK6, ALK-6, CDw293 -BMPR1B and Breast Cancer
4
RBP1 3q23 CRBP, RBPC, CRBP1, CRBPI, CRABP-I -RBP1 and Breast Cancer
4
RAD54L 1p32 HR54, hHR54, RAD54A, hRAD54 -RAD54L and Breast Cancer
4
LRIG1 3p14 LIG1, LIG-1 -LRIG1 and Breast Cancer
4
MYCN 2p24.3 NMYC, ODED, MODED, N-myc, bHLHe37 -MYCN and Breast Cancer
4
CASP6 4q25 MCH2 -CASP6 and Breast Cancer
4
PTMS 12p13 ParaT -PTMS and Breast Cancer
4
PINX1 8p23 LPTL, LPTS -PINX1 and Breast Cancer
4
CD69 12p13 AIM, EA1, MLR-3, CLEC2C, GP32/28, BL-AC/P26 -CD69 and Breast Cancer
4
HOXC11 12q13.3 HOX3H -HOXC11 and Breast Cancer
4
GAS6 13q34 AXSF, AXLLG -GAS6 and Breast Cancer
4
CXCL5 4q13.3 SCYB5, ENA-78 -CXCL5 and Breast Cancer
4
TP53INP1 8q22 SIP, Teap, p53DINP1, TP53DINP1, TP53INP1A, TP53INP1B -TP53INP1 and Breast Cancer
4
SEMA3A 7p12.1 HH16, SemD, COLL1, SEMA1, SEMAD, SEMAL, coll-1, Hsema-I, SEMAIII, Hsema-III -SEMA3A and Breast Cancer
4
ABCA1 9q31.1 TGD, ABC1, CERP, ABC-1, HDLDT1 -ABCA1 and Breast Cancer
4
SPHK1 17q25.2 SPHK -SPHK1 and Breast Cancer
4
NDRG2 14q11.2 SYLD -NDRG2 and Breast Cancer
4
SSTR5 16p13.3 SS-5-R -SSTR5 and Breast Cancer
4
BCL2L12 19q13.3 -BCL2L12 and Breast Cancer
4
KIAA1524 3q13.13 p90, CIP2A -KIAA1524 and Breast Cancer
4
TBK1 12q14.1 NAK, T2K -TBK1 and Breast Cancer
4
KRT14 17q21.2 K14, NFJ, CK14, EBS3, EBS4 -KRT14 and Breast Cancer
4
CCNG1 5q32-q34 CCNG -CCNG1 and Breast Cancer
4
CD163 12p13.3 M130, MM130 -CD163 and Breast Cancer
4
LRP1 12q13.3 APR, LRP, A2MR, CD91, APOER, LRP1A, TGFBR5, IGFBP3R -LRP1 and Breast Cancer
4
RBX1 22q13.2 ROC1, RNF75, BA554C12.1 -RBX1 and Breast Cancer
4
GMNN 6p22.3 Gem -GMNN and Breast Cancer
4
PRDX1 1p34.1 PAG, PAGA, PAGB, PRX1, PRXI, MSP23, NKEFA, TDPX2, NKEF-A -PRDX1 and Breast Cancer
4
MIR10A 17q21.32 MIRN10A, mir-10a, miRNA10A, hsa-mir-10a -miR-10a and Breast Cancer
4
SMARCA2 9p22.3 BRM, SNF2, SWI2, hBRM, NCBRS, Sth1p, BAF190, SNF2L2, SNF2LA, hSNF2a -SMARCA2 and Breast Cancer
4
PLAGL1 6q24-q25 ZAC, LOT1, ZAC1 -PLAGL1 and Breast Cancer
4
CCL3 17q12 MIP1A, SCYA3, G0S19-1, LD78ALPHA, MIP-1-alpha -CCL3 and Breast Cancer
4
AVPR1A 12q14-q15 V1aR, AVPR1, AVPR V1a -AVPR1A and Breast Cancer
4
ANO1 11q13.3 DOG1, TAOS2, ORAOV2, TMEM16A -ANO1 and Breast Cancer
4
HPSE 4q21.3 HPA, HPA1, HPR1, HSE1, HPSE1 -HPSE and Breast Cancer
4
FABP7 6q22-q23 MRG, BLBP, FABPB, B-FABP, LTR2-FABP7 -FABP7 and Breast Cancer
4
TFRC 3q29 T9, TR, TFR, p90, CD71, TFR1, TRFR -TFRC and Breast Cancer
4
CD276 15q23-q24 B7H3, B7-H3, B7RP-2, 4Ig-B7-H3 -CD276 and Breast Cancer
4
PHIP 6q14 ndrp, BRWD2, WDR11, DCAF14 -PHIP and Breast Cancer
4
CD151 11p15.5 GP27, MER2, RAPH, SFA1, PETA-3, TSPAN24 -CD151 and Breast Cancer
4
CX3CL1 16q13 NTN, NTT, CXC3, CXC3C, SCYD1, ABCD-3, C3Xkine, fractalkine, neurotactin -CX3CL1 and Breast Cancer
4
MIRLET7G 3p21.1 LET7G, MIRNLET7G, hsa-let-7g -MicroRNA let-7g and Breast Cancer
4
ST14 11q24-q25 HAI, MTSP1, SNC19, ARCI11, MT-SP1, PRSS14, TADG15, TMPRSS14 -ST14 and Breast Cancer
4
EGLN3 14q13.1 PHD3, HIFPH3, HIFP4H3 -EGLN3 and Breast Cancer
4
FLNC 7q32-q35 ABPA, ABPL, FLN2, MFM5, MPD4, ABP-280, ABP280A -FLNC and Breast Cancer
4
AQP1 7p14 CO, CHIP28, AQP-CHIP -AQP1 and Breast Cancer
4
SKIL 3q26 SNO, SnoA, SnoI, SnoN -SKIL and Breast Cancer
4
MUC5B 11p15.5 MG1, MUC5, MUC9, MUC-5B -MUC5B and Breast Cancer
4
TRADD 16q22 Hs.89862 -TRADD and Breast Cancer
4
RECQL4 8q24.3 RECQ4 -RECQL4 and Breast Cancer
4
AVPR1B 1q32 AVPR3 -AVPR1B and Breast Cancer
4
FGR 1p36.2-p36.1 SRC2, c-fgr, c-src2, p55-Fgr, p58-Fgr, p55c-fgr, p58c-fgr -FGR and Breast Cancer
4
SMPD1 11p15.4-p15.1 ASM, NPD, ASMASE -SMPD1 and Breast Cancer
4
MCM7 7q21.3-q22.1 MCM2, CDC47, P85MCM, P1CDC47, PNAS146, PPP1R104, P1.1-MCM3 -MCM7 and Breast Cancer
4
THRA 17q11.2 AR7, EAR7, ERBA, CHNG6, ERBA1, NR1A1, THRA1, THRA2, ERB-T-1, c-ERBA-1 -THRA and Breast Cancer
4
PPIA 7p13 CYPA, CYPH, HEL-S-69p -PPIA and Breast Cancer
4
PLA2G4A 1q25 PLA2G4, cPLA2-alpha -PLA2G4A and Breast Cancer
4
MELK 9p13.2 HPK38 -MELK and Breast Cancer
4
HYAL1 3p21.31 NAT6, LUCA1, HYAL-1 -HYAL1 and Breast Cancer
4
FSCN1 7p22 HSN, SNL, p55, FAN1 -FSCN1 and Breast Cancer
4
SLC9A1 1p36.1-p35 APNH, NHE1, NHE-1, PPP1R143 -SLC9A1 and Breast Cancer
4
CXCR5 11q23.3 BLR1, CD185, MDR15 -CXCR5 and Breast Cancer
4
NFATC2 20q13.2 NFAT1, NFATP -NFATC2 and Breast Cancer
4
PARK7 1p36.23 DJ1, DJ-1, HEL-S-67p -PARK7 and Breast Cancer
4
GNB2L1 5q35.3 H12.3, HLC-7, PIG21, RACK1, Gnb2-rs1 -GNB2L1 and Breast Cancer
4
DLL4 15q14 hdelta2 -DLL4 and Breast Cancer
4
SSTR1 14q13 SS1R, SS1-R, SRIF-2, SS-1-R -SSTR1 and Breast Cancer
4
MAPK14 6p21.3-p21.2 RK, p38, CSBP, EXIP, Mxi2, CSBP1, CSBP2, CSPB1, PRKM14, PRKM15, SAPK2A, p38ALPHA -MAPK14 and Breast Cancer
4
CASP5 11q22.2-q22.3 ICH-3, ICEREL-III, ICE(rel)III -CASP5 and Breast Cancer
4
NOV 8q24.1 CCN3, NOVh, IBP-9, IGFBP9, IGFBP-9 -NOV and Breast Cancer
4
LINC00632 Xq27.1 -RP1-177G6.2 and Breast Cancer
4
LAPTM4B 8q22.1 LC27, LAPTM4beta -LAPTM4B and Breast Cancer
4
CTSL 9q21.33 MEP, CATL, CTSL1 -CTSL1 and Breast Cancer
4
TYRO3 15q15 BYK, Dtk, RSE, Rek, Sky, Tif, Etk-2 -TYRO3 and Breast Cancer
4
DUSP6 12q22-q23 HH19, MKP3, PYST1 -DUSP6 and Breast Cancer
4
MUC16 19p13.2 CA125 -MUC16 and Breast Cancer
4
TBX21 17q21.32 TBET, T-PET, T-bet, TBLYM -TBX21 and Breast Cancer
4
STRADA 17q23.3 LYK5, PMSE, Stlk, STRAD, NY-BR-96 -STRADA and Breast Cancer
4
BANP 16q24 BEND1, SMAR1, SMARBP1 -BANP and Breast Cancer
4
ARID4A 14q23.1 RBP1, RBBP1, RBP-1, RBBP-1 -ARID4A and Breast Cancer
4
HTATIP2 11p15.1 CC3, TIP30, SDR44U1 -HTATIP2 and Breast Cancer
4
DUSP4 8p12-p11 TYP, HVH2, MKP2, MKP-2 -DUSP4 and Breast Cancer
4
KLLN 10q23 CWS4, KILLIN -KLLN and Breast Cancer
4
TDGF1 3p21.31 CR, CRGF, CRIPTO -TDGF1 and Breast Cancer
4
SPRY1 4q28.1 hSPRY1 -SPRY1 and Breast Cancer
4
ITGB2 21q22.3 LAD, CD18, MF17, MFI7, LCAMB, LFA-1, MAC-1 -ITGB2 and Breast Cancer
4
SRD5A1 5p15 S5AR 1 -SRD5A1 and Breast Cancer
3
LZTS1 8p22 F37, FEZ1 -LZTS1 and Breast Cancer
3
CCNC 6q21 CycC -CCNC and Breast Cancer
3
LRP1B 2q21.2 LRPDIT, LRP-DIT -LRP1B and Breast Cancer
3
SMYD3 1q44 KMT3E, ZMYND1, ZNFN3A1, bA74P14.1 -SMYD3 and Breast Cancer
3
DEC1 9q32 CTS9 -DEC1 and Breast Cancer
3
NOX4 11q14.2-q21 KOX, KOX-1, RENOX -NOX4 and Breast Cancer
3
NOTO 2p13.2 -NOTO and Breast Cancer
3
MBD1 18q21 RFT, PCM1, CXXC3 -MBD1 and Breast Cancer
3
FUT4 11q21 LeX, CD15, ELFT, FCT3A, FUTIV, SSEA-1, FUC-TIV -FUT4 and Breast Cancer
3
TRAF1 9q33-q34 EBI6, MGC:10353 -TRAF1 and Breast Cancer
3
POU2F1 1q24.2 OCT1, OTF1, oct-1B -POU2F1 and Breast Cancer
3
SOX18 20q13.33 HLTS -SOX18 and Breast Cancer
3
FER 5q21 FerT, TYK3, Pe1Fe3, Pe1Fe6, PPP1R74, Pe1Fe10, Pe1Fe13 -FER and Breast Cancer
3
MYH9 22q13.1 MHA, FTNS, EPSTS, BDPLT6, DFNA17, NMMHCA, NMHC-II-A, NMMHC-IIA -MYH9 and Breast Cancer
3
PPP2R1A 19q13.41 PR65A, PP2AAALPHA, PP2A-Aalpha -PPP2R1A and Breast Cancer
3
COL4A2 13q34 ICH, POREN2 -COL4A2 and Breast Cancer
3
ENO1 1p36.2 NNE, PPH, MPB1, ENO1L1 -ENO1 and Breast Cancer
3
RBM5 3p21.3 G15, H37, RMB5, LUCA15 -RBM5 and Breast Cancer
3
ZBTB7A 19p13.3 LRF, FBI1, FBI-1, ZBTB7, ZNF857A, pokemon -ZBTB7A and Breast Cancer
3
DLEC1 3p21.3 F56, DLC1, CFAP81 -DLEC1 and Breast Cancer
3
CDCP1 3p21.31 CD318, TRASK, SIMA135 -CDCP1 and Breast Cancer
3
POLB 8p11.2 -POLB and Breast Cancer
3
IMP3 15q24 BRMS2, MRPS4, C15orf12 -IMP3 and Breast Cancer
3
TLE1 9q21.32 ESG, ESG1, GRG1 -TLE1 and Breast Cancer
3
PRKCDBP 11p15.4 SRBC, HSRBC, CAVIN3, cavin-3 -PRKCDBP and Breast Cancer
3
RAG1 11p13 RAG-1, RNF74 -RAG1 and Breast Cancer
3
CHI3L1 1q32.1 GP39, ASRT7, GP-39, YKL40, CGP-39, YKL-40, YYL-40, HC-gp39, HCGP-3P, hCGP-39 -CHI3L1 and Breast Cancer
3
MUC3A 7q22 MUC3, MUC-3A -MUC3A and Breast Cancer
3
CD59 11p13 1F5, EJ16, EJ30, EL32, G344, MIN1, MIN2, MIN3, MIRL, HRF20, MACIF, MEM43, MIC11, MSK21, 16.3A5, HRF-20, MAC-IP, p18-20 -CD59 and Breast Cancer
3
RALGDS 9q34.3 RGF, RGDS, RalGEF -RALGDS and Breast Cancer
3
ROCK2 2p24 ROCK-II -ROCK2 and Breast Cancer
3
OCLN 5q13.1 BLCPMG, PPP1R115 -OCLN and Breast Cancer
3
GRASP 12q13.13 TAMALIN -GRASP and Breast Cancer
3
MAP2K6 17q24.3 MEK6, MKK6, MAPKK6, PRKMK6, SAPKK3, SAPKK-3 -MAP2K6 and Breast Cancer
3
MAP3K5 6q22.33 ASK1, MEKK5, MAPKKK5 -MAP3K5 and Breast Cancer
3
JAG2 14q32 HJ2, SER2 -JAG2 and Breast Cancer
3
TNFRSF10D 8p21 DCR2, CD264, TRUNDD, TRAILR4, TRAIL-R4 -TNFRSF10D and Breast Cancer
3
CHAT 10q11.2 CMS1A, CMS1A2, CHOACTASE -CHAT and Breast Cancer
3
KDM4C 9p24.1 GASC1, JHDM3C, JMJD2C, TDRD14C, bA146B14.1 -KDM4C and Breast Cancer
3
PROX1 1q41 -PROX1 and Breast Cancer
3
GRM1 6q24 MGLU1, GPRC1A, MGLUR1, SCAR13, PPP1R85 -GRM1 and Breast Cancer
3
ROCK1 18q11.1 ROCK-I, P160ROCK -ROCK1 and Breast Cancer
3
USP7 16p13.3 TEF1, HAUSP -USP7 and Breast Cancer
3
TRIM24 7q32-q34 PTC6, TF1A, TIF1, RNF82, TIF1A, hTIF1, TIF1ALPHA -TRIM24 and Breast Cancer
3
BCL11A 2p16.1 EVI9, CTIP1, ZNF856, HBFQTL5, BCL11A-L, BCL11A-S, BCL11a-M, BCL11A-XL Amplification
Overexpression
-BCL11A Overexpression and Amplification Breast Cancer
3
DLG1 3q29 hdlg, DLGH1, SAP97, SAP-97, dJ1061C18.1.1 -DLG1 and Breast Cancer
3
WNT7A 3p25 -WNT7A and Breast Cancer
3
LDHA 11p15.4 LDH1, LDHM, GSD11, PIG19, HEL-S-133P -LDHA and Breast Cancer
3
GREM1 15q13.3 DRM, HMPS, MPSH, PIG2, CRAC1, CRCS4, DAND2, HMPS1, IHG-2, DUP15q, C15DUPq, GREMLIN, CKTSF1B1 -GREM1 and Breast Cancer
3
NKX2-5 5q34 CSX, CSX1, VSD3, CHNG5, HLHS2, NKX2E, NKX2.5, NKX4-1 -NKX2-5 and Breast Cancer
3
RARRES3 11q23 RIG1, TIG3, HRSL4, HRASLS4, PLA1/2-3 -RARRES3 and Breast Cancer
3
SLPI 20q12 ALP, MPI, ALK1, BLPI, HUSI, WAP4, WFDC4, HUSI-I -SLPI and Breast Cancer
3
BTG1 12q22 -BTG1 and Breast Cancer
3
TRAF6 11p12 RNF85, MGC:3310 -TRAF6 and Breast Cancer
3
SLC5A8 12q23.1 AIT, SMCT, SMCT1 -SLC5A8 and Breast Cancer
3
MAGEB2 Xp21.3 DAM6, CT3.2, MAGE-XP-2 -MAGEB2 and Breast Cancer
3
RAD23B 9q31.2 P58, HR23B, HHR23B -RAD23B and Breast Cancer
3
MKL1 22q13 MAL, BSAC, MRTF-A -MKL1 and Breast Cancer
3
SNRPN 15q11.2 SMN, PWCR, SM-D, sm-N, RT-LI, HCERN3, SNRNP-N, SNURF-SNRPN -SNRPN and Breast Cancer
3
BAGE 21p11.1 BAGE1, CT2.1 -BAGE and Breast Cancer
3
LDLR 19p13.2 FH, FHC, LDLCQ2 -LDLR and Breast Cancer
3
HRK 12q24.22 DP5, HARAKIRI -HRK and Breast Cancer
3
BCL3 19q13.1-q13.2 BCL4, D19S37 -BCL3 and Breast Cancer
3
MTUS1 8p22 ATBP, ATIP, ICIS, MP44, MTSG1 -MTUS1 and Breast Cancer
3
MINA 3q11.2 ROX, MDIG, NO52, MINA53 -MINA and Breast Cancer
3
STIM1 11p15.5 GOK, TAM, TAM1, IMD10, STRMK, D11S4896E -STIM1 and Breast Cancer
3
CASP2 7q34-q35 ICH1, NEDD2, CASP-2, NEDD-2, PPP1R57 -CASP2 and Breast Cancer
3
GALM 2p22.1 GLAT, IBD1, BLOCK25, HEL-S-63p -GALM and Breast Cancer
3
MSI1 12q24 -MSI1 and Breast Cancer
3
NOX1 Xq22 MOX1, NOH1, NOH-1, GP91-2 -NOX1 and Breast Cancer
3
CCR4 3p24 CKR4, K5-5, CD194, CMKBR4, ChemR13, CC-CKR-4, HGCN:14099 -CCR4 and Breast Cancer
3
MT2A 16q13 MT2 -MT2A and Breast Cancer
3
MT1G 16q13 MT1, MT1K -MT1G and Breast Cancer
3
SLCO1B3 12p12 LST3, HBLRR, LST-2, OATP8, OATP-8, OATP1B3, SLC21A8, LST-3TM13 -SLCO1B3 and Breast Cancer
3
ROR1 1p32-p31 NTRKR1, dJ537F10.1 -ROR1 and Breast Cancer
3
WWTR1 3q23-q24 TAZ -WWTR1 and Breast Cancer
3
PITX1 5q31.1 BFT, CCF, POTX, PTX1, LBNBG -PITX1 and Breast Cancer
3
HPGD 4q34-q35 PGDH, PGDH1, PHOAR1, 15-PGDH, SDR36C1 -HPGD and Breast Cancer
3
CCL22 16q13 MDC, ABCD-1, SCYA22, STCP-1, DC/B-CK, A-152E5.1 -CCL22 and Breast Cancer
3
CRY1 12q23-q24.1 PHLL1 -CRY1 and Breast Cancer
3
RARRES1 3q25.32 LXNL, TIG1 -RARRES1 and Breast Cancer
3
CXCL16 17p13 SRPSOX, CXCLG16, SR-PSOX -CXCL16 and Breast Cancer
3
IL4R 16p12.1-p11.2 CD124, IL4RA, IL-4RA -IL4R and Breast Cancer
3
WNT5B 12p13.3 -WNT5B and Breast Cancer
3
EPB41L3 18p11.32 4.1B, DAL1, DAL-1 -EPB41L3 and Breast Cancer
3
CDK9 9q34.1 TAK, C-2k, CTK1, CDC2L4, PITALRE -CDK9 and Breast Cancer
3
BOLL 2q33 BOULE -BOLL and Breast Cancer
3
NNAT 20q11.2-q12 Peg5 -NNAT and Breast Cancer
3
RAD17 5q13 CCYC, R24L, RAD24, HRAD17, RAD17SP -RAD17 and Breast Cancer
3
IL23R 1p31.3 -IL23R and Breast Cancer
3
LGALS4 19q13.2 GAL4, L36LBP -LGALS4 and Breast Cancer
3
MALAT1 11q13.1 HCN, NEAT2, MALAT-1, PRO2853, mascRNA, LINC00047, NCRNA00047 -MALAT1 and Breast Cancer
3
LIPA 10q23.2-q23.3 LAL, CESD -LIPA and Breast Cancer
3
FGF19 11q13.1 -FGF19 and Breast Cancer
3
FCGR2A 1q23 CD32, FCG2, FcGR, CD32A, CDw32, FCGR2, IGFR2, FCGR2A1 -FCGR2A and Breast Cancer
3
HTRA1 10q26.3 L56, HtrA, ARMD7, ORF480, PRSS11, CARASIL -HTRA1 and Breast Cancer
3
IRAK2 3p25.3 IRAK-2 -IRAK2 and Breast Cancer
3
AKAP9 7q21-q22 LQT11, PRKA9, AKAP-9, CG-NAP, YOTIAO, AKAP350, AKAP450, PPP1R45, HYPERION, MU-RMS-40.16A -AKAP9 and Breast Cancer
3
PRKCE 2p21 PKCE, nPKC-epsilon -PRKCE and Breast Cancer
3
CTSB 8p22 APPS, CPSB -CTSB and Breast Cancer
3
ANGPT1 8q23.1 AGP1, AGPT, ANG1 -ANGPT1 and Breast Cancer
3
GADD45B 19p13.3 MYD118, GADD45BETA -GADD45B and Breast Cancer
3
PRKCD 3p21.31 MAY1, PKCD, ALPS3, CVID9, nPKC-delta -PRKCD and Breast Cancer
3
CTCFL 20q13.31 CT27, BORIS, CTCF-T, HMGB1L1, dJ579F20.2 -CTCFL and Breast Cancer
3
SERPINC1 1q25.1 AT3, AT3D, ATIII, THPH7 -SERPINC1 and Breast Cancer
2
TTL 2q13 -TTL and Breast Cancer
2
ODC1 2p25 ODC -ODC1 and Breast Cancer
2
IL32 16p13.3 NK4, TAIF, TAIFa, TAIFb, TAIFc, TAIFd, IL-32beta, IL-32alpha, IL-32delta, IL-32gamma -IL32 and Breast Cancer
2
FEZ1 11q24.2 -FEZ1 and Breast Cancer
2
MME 3q25.2 NEP, SFE, CD10, CALLA -MME and Breast Cancer
2
HSP90AA1 14q32.33 EL52, HSPN, LAP2, HSP86, HSPC1, HSPCA, Hsp89, Hsp90, LAP-2, HSP89A, HSP90A, HSP90N, HSPCAL1, HSPCAL4 -HSP90AA1 and Breast Cancer
2
SDC4 20q12 SYND4 -SDC4 and Breast Cancer
2
HAS3 16q22.1 -HAS3 and Breast Cancer
2
PERP 6q24 THW, KCP1, PIGPC1, KRTCAP1, dJ496H19.1 -PERP and Breast Cancer
2
SOX5 12p12.1 L-SOX5, L-SOX5B, L-SOX5F -SOX5 and Breast Cancer
2
SLC22A18 11p15.5 HET, ITM, BWR1A, IMPT1, TSSC5, ORCTL2, BWSCR1A, SLC22A1L, p45-BWR1A -SLC22A18 and Breast Cancer
2
CD200 3q13.2 MRC, MOX1, MOX2, OX-2 -CD200 and Breast Cancer
2
IL1RL1 2q12 T1, ST2, DER4, ST2L, ST2V, FIT-1, IL33R -IL1RL1 and Breast Cancer
2
GJB2 13q11-q12 HID, KID, PPK, CX26, DFNA3, DFNB1, NSRD1, DFNA3A, DFNB1A -GJB2 and Breast Cancer
2
PDGFRL 8p22-p21.3 PDGRL, PRLTS -PDGFRL and Breast Cancer
2
TPM4 19p13.1 HEL-S-108 -TPM4 and Breast Cancer
2
ABCB5 7p21.1 ABCB5beta, EST422562, ABCB5alpha -ABCB5 and Breast Cancer
2
TP53BP2 1q41 BBP, 53BP2, ASPP2, P53BP2, PPP1R13A -TP53BP2 and Breast Cancer
2
AGTR2 Xq22-q23 AT2, ATGR2, MRX88 -AGTR2 and Breast Cancer
2
HSD11B1 1q32-q41 HDL, 11-DH, HSD11, HSD11B, HSD11L, CORTRD2, SDR26C1, 11-beta-HSD1 -HSD11B1 and Breast Cancer
2
RNF217-AS1 6q22.33 STL -STL and Breast Cancer
2
PATZ1 22q12.2 ZSG, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, dJ400N23 -PATZ1 and Breast Cancer
2
ACSL3 2q34-q35 ACS3, FACL3, PRO2194 -ACSL3 and Breast Cancer
2
USP6 17p13 HRP1, TRE2, TRE17, Tre-2, TRESMCR, USP6-short -USP6 and Breast Cancer
2
ARF1 1q42 -ARF1 and Breast Cancer
2
AKAP13 15q24-q25 BRX, LBC, p47, HA-3, Ht31, c-lbc, PRKA13, AKAP-13, AKAP-Lbc, ARHGEF13, PROTO-LB, PROTO-LBC -AKAP13 and Breast Cancer
2
DGCR8 22q11.2 Gy1, pasha, DGCRK6, C22orf12 -DGCR8 and Breast Cancer
2
GLIPR1 12q21.2 GLIPR, RTVP1, CRISP7 -GLIPR1 and Breast Cancer
2
C2orf40 2q12.2 ECRG4 -C2orf40 and Breast Cancer
2
TSPO 22q13.31 DBI, IBP, MBR, PBR, PBS, BPBS, BZRP, PKBS, PTBR, mDRC, pk18 -TSPO and Breast Cancer
2
GUSB 7q21.11 BG, MPS7 -GUSB and Breast Cancer
2
GALT 9p13 -GALT and Breast Cancer
2
IL12B 5q31.1-q33.1 CLMF, NKSF, CLMF2, IMD28, IMD29, NKSF2, IL-12B -IL12B and Breast Cancer
2
ZNF331 19q13.42 RITA, ZNF361, ZNF463 -ZNF331 and Breast Cancer
2
GJA1 6q22.31 HSS, CMDR, CX43, GJAL, ODDD, AVSD3, HLHS1 -GJA1 and Breast Cancer
2
TM4SF1 3q21-q25 L6, H-L6, M3S1, TAAL6 -TM4SF1 and Breast Cancer
2
EPHA5 4q13.1 EK7, CEK7, EHK1, HEK7, EHK-1, TYRO4 -EPHA5 and Breast Cancer
2
PCM1 8p22-p21.3 PTC4 -PCM1 and Breast Cancer
2
MYCBP 1p33-p32.2 AMY-1 -MYCBP and Breast Cancer
2
MIR10B 2q31.1 MIRN10B, mir-10b, miRNA10B, hsa-mir-10b -MIR10B and Breast Cancer
2
EPHA1 7q34 EPH, EPHT, EPHT1 -EPHA1 and Breast Cancer
2
ACVRL1 12q13.13 HHT, ALK1, HHT2, ORW2, SKR3, ALK-1, TSR-I, ACVRLK1 -ACVRL1 and Breast Cancer
2
TLR6 4p14 CD286 -TLR6 and Breast Cancer
2
CTDSPL 3p21.3 PSR1, SCP3, HYA22, RBSP3, C3orf8 -CTDSPL and Breast Cancer
2
MAX 14q23 bHLHd4 -MAX and Breast Cancer
2
PRDX6 1q25.1 PRX, p29, AOP2, 1-Cys, NSGPx, aiPLA2, HEL-S-128m -PRDX6 and Breast Cancer
2
TRIM27 6p22 RFP, RNF76 -TRIM27 and Breast Cancer
2
ESPL1 12q ESP1, SEPA -ESPL1 and Breast Cancer
2
ATP7A Xq21.1 MK, MNK, DSMAX, SMAX3 -ATP7A and Breast Cancer
2
PTPRK 6q22.2-q22.3 R-PTP-kappa -PTPRK and Breast Cancer
2
MAP3K8 10p11.23 COT, EST, ESTF, TPL2, MEKK8, Tpl-2, c-COT -MAP3K8 and Breast Cancer
2
UCP2 11q13 UCPH, BMIQ4, SLC25A8 -UCP2 and Breast Cancer
2
PAWR 12q21 PAR4, Par-4 -PAWR and Breast Cancer
2
VCAM1 1p32-p31 CD106, INCAM-100 -VCAM1 and Breast Cancer
2
ELK4 1q32 SAP1 -ELK4 and Breast Cancer
2
RABEP1 17p13.2 RAB5EP, RABPT5 -RABEP1 and Breast Cancer
2
RAP1GDS1 4q23-q25 GDS1, SmgGDS -RAP1GDS1 and Breast Cancer
2
FSTL3 19p13 FLRG, FSRP -FSTL3 and Breast Cancer
2
LIMD1 3p21.3 -LIMD1 and Breast Cancer
2
EXTL1 1p36.1 EXTL -EXTL1 and Breast Cancer
1
KAT6B 10q22.2 qkf, MORF, MOZ2, GTPTS, MYST4, ZC2HC6B, querkopf -KAT6B and Breast Cancer
1
GPRC6A 6q22.1 GPCR, bA86F4.3 -GPRC6A and Breast Cancer
1
ARHGEF5 7q35 P60, TIM, GEF5, TIM1 -ARHGEF5 and Breast Cancer
1
SRGAP3 3p25.3 WRP, MEGAP, SRGAP2, ARHGAP14 -SRGAP3 and Breast Cancer
1
S100A3 1q21 S100E -S100A3 and Breast Cancer
1
CTNND1 11q11 CAS, p120, CTNND, P120CAS, P120CTN, p120(CAS), p120(CTN) -CTNND1 and Breast Cancer
1
CRTC3 15q26.1 TORC3, TORC-3 -CRTC3 and Breast Cancer
1
ETV3 1q21-q23 PE1, METS, PE-1, bA110J1.4 -ETV3 and Breast Cancer
1
PLCD1 3p22-p21.3 NDNC3, PLC-III -PLCD1 and Breast Cancer
1
COX6C 8q22.2 -COX6C and Breast Cancer
1
EIF4A2 3q28 DDX2B, EIF4A, EIF4F, BM-010, eIF4A-II, eIF-4A-II -EIF4A2 and Breast Cancer
1
PNN 14q21.1 DRS, DRSP, SDK3, memA -PNN and Breast Cancer
1
ARHGEF12 11q23.3 LARG, PRO2792 -ARHGEF12 and Breast Cancer
1
KMT2D 12q13.12 ALR, KMS, MLL2, MLL4, AAD10, KABUK1, TNRC21, CAGL114 -KMT2D and Breast Cancer
1
ERC1 12p13.3 ELKS, Cast2, ERC-1, RAB6IP2 -ERC1 and Breast Cancer
1
TRG 7p14 TCRG, TRG@ -TRG and Breast Cancer
1
HOXC10 12q13.3 HOX3I Epigenetics
-HOXC10 Silencing in ER positive Breast Cancer

Note: list is not exhaustive. Number of papers are based on searches of PubMed (click on topic title for arbitrary criteria used).


Latest Publications

Bhatnagar S, Gazin C, Chamberlain L, et al.
TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein.
Nature. 2014; 516(7529):116-20 [PubMed] Article available free on PMC after 04/06/2015 Related Publications
The TRIM37 (also known as MUL) gene is located in the 17q23 chromosomal region, which is amplified in up to ∼ 40% of breast cancers. TRIM37 contains a RING finger domain, a hallmark of E3 ubiquitin ligases, but its protein substrate(s) is unknown. Here we report that TRIM37 mono-ubiquitinates histone H2A, a chromatin modification associated with transcriptional repression. We find that in human breast cancer cell lines containing amplified 17q23, TRIM37 is upregulated and, reciprocally, the major H2A ubiquitin ligase RNF2 (also known as RING1B) is downregulated. Genome-wide chromatin immunoprecipitation (ChIP)-chip experiments in 17q23-amplified breast cancer cells identified many genes, including multiple tumour suppressors, whose promoters were bound by TRIM37 and enriched for ubiquitinated H2A. However, unlike RNF2, which is a subunit of polycomb repressive complex 1 (PRC1), we find that TRIM37 associates with polycomb repressive complex 2 (PRC2). TRIM37, PRC2 and PRC1 are co-bound to specific target genes, resulting in their transcriptional silencing. RNA-interference-mediated knockdown of TRIM37 results in loss of ubiquitinated H2A, dissociation of PRC1 and PRC2 from target promoters, and transcriptional reactivation of silenced genes. Knockdown of TRIM37 in human breast cancer cells containing amplified 17q23 substantially decreases tumour growth in mouse xenografts. Conversely, ectopic expression of TRIM37 renders non-transformed cells tumorigenic. Collectively, our results reveal TRIM37 as an oncogenic H2A ubiquitin ligase that is overexpressed in a subset of breast cancers and promotes transformation by facilitating silencing of tumour suppressors and other genes.


Lee HJ, Seo AN, Kim EJ, et al.
HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Am J Clin Pathol. 2014; 142(6):755-66 [PubMed] Related Publications
OBJECTIVES: Heterogeneity of HER2 gene amplification is found in a subset of breast cancers. We investigated the impact of HER2 heterogeneity on trastuzumab responses and clinical outcomes in 112 patients with HER2-positive metastatic breast cancer.
METHODS: Regional and genetic heterogeneity of HER2 gene amplification was determined in three different areas of each tumor by immunohistochemistry and silver in situ hybridization. We also assessed the overall levels of HER2 amplification and the proportion of tumor cells with a HER2/CEP17 ratio of more than 2.2 or strong and complete membranous (3+) expression of HER2 protein.
RESULTS: HER2 regional and genetic heterogeneity based on the HER2/CEP17 ratio was confirmed in 8.7% and 2.7% of cases, respectively. Poor response to trastuzumab was associated with overall low-level or equivocal amplification, HER2 regional heterogeneity by the HER2/CEP17 ratio, the HER2/CEP17 ratio of more than 2.2 in less than 80% of tumor cells, and HER2 immunohistochemical expression of 3+ in less than 75% of tumor cells. In survival analyses, low-level or equivocal HER2 amplification, HER2 regional heterogeneity based on the HER2/CEP17 ratio, and the HER2/CEP17 ratio of more than 2.2 in less than 80% of tumor cells were associated with shorter time to progression and lower overall survival in univariate and multivariate analyses.
CONCLUSIONS: These results suggest that accurate assessment of HER2 status, including HER2 heterogeneity, is important in predicting trastuzumab responses and outcomes in patients with HER2-positive metastatic breast cancer.

Related: ERBB2 (HER2) Trastuzumab (Herceptin)


Ottini L
Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer.
Nat Rev Cancer. 2014; 14(10):643 [PubMed] Related Publications
There are similarities between breast cancers that arise in men and women but there are also differences. What can be learned from male breast cancer to gain insight into breast cancer pathogenesis?

Related: Male Breast Cancer BRCA1 BRCA2 Signal Transduction


Wood WC, Alvarado M, Buchholz DJ, et al.
The current clinical value of the DCIS Score.
Oncology (Williston Park). 2014; 28 Suppl 2:C2, 1-8, C3 [PubMed] Related Publications
The management of ductal carcinoma in situ (DCIS) can be controversial. Widespread adoption of mammographic screening has made DCIS a more frequent diagnosis, and increasingly smaller, lower-grade lesions are being detected. DCIS is commonly treated with breast-conserving surgery and radiation. However, there is greater recognition that acceptable cancer control outcomes can be achieved for some patients with breast-conserving surgery alone, with radiotherapy reserved for those at higher risk of in-breast recurrence. The primary clinical dilemma is that there are currently no reliable clinicopathologic features that accurately predict which patients will have a recurrence, but risk stratification is an area of active research. Molecular profiling has the potential to assess recurrence risk based on the individual patient's tumor biology and guide treatment decisions. The DCIS Score is a 12-gene assay intended to support personalized treatment planning for patients with DCIS following local excision. It provides information on local failure risk independent of traditional clinicopathologic features. Our group of expert breast surgeons and radiation oncologists met in December 2013 at the San Antonio Breast Cancer Symposium to discuss current controversies in DCIS management and determine the potential value of the DCIS Score in managing these situations. We concluded that the DCIS Score provides clinically relevant information about personal risk that can guide patient discussions and facilitate shared decision making.


Matsionis AE, Petrov AV, Gorelik MZ, Zavalishina LE
[Numerical impairments in genes in breast cancer: a multiplex ligation-dependent probe amplification study].
Arkh Patol. 2014 Jul-Aug; 76(4):15-7 [PubMed] Related Publications
OBJECTIVE: To analyze breast cancer samples using the new technique multiplex ligation-dependent probe amplification (MLPA) assay. MATERIAL AND METHODS; Formalin-fixed paraffin-embedded breast carcinoma samples from 65 patients were examined. After manual microdissection, DNA was isolated using a commercial kit ("QIAGEN") and analyzed with SALSA MLPA KIT P078-B1 Breast Tumour ("MRC-Holland"). Capillary electrophoresis provided results.
RESULTS: MLPA assay was successful in all examined samples. The amplification and deletion frequencies of the analyzed genes were in line with the literature data. The technique requires conventional work-related skills in a molecular genetic laboratory and, as a whole, presents no problems with its usage. The interpretation of results is devoid of subjective meaning due to exclusively their mathematical analysis. MLPA assay provides an insight into numerical impairments in the following genes: ERBB2, MYC, TRAF4, C11orf30 (EMSY), ADAM9, IKBKB, CCNE1, TOP2A, CDH1, CDC6, ESR1, CPD, EGFR, MTDH, CCND1, BIRC5, MED1, FGFR1, MAPT, PRDM14, and AURKA.
CONCLUSION: MLPA is an easy-to-use and promising method for multiplex genetic analysis of tumor cells in breast cancer.

Related: FISH


Hill J, Hodsdon W
In utero exposure and breast cancer development: an epigenetic perspective.
J Environ Pathol Toxicol Oncol. 2014; 33(3):239-45 [PubMed] Related Publications
The ubiquitous and detrimental disease of breast cancer requires continual research into new and alternative forms of treatment and prevention. The emerging field of epigenetics is beginning to unfold an array of contemporary approaches to reduce the risk and improve the clinical approach to breast cancer. The information contained in this non-systematic review highlights and expands on the estrogen-based model of breast cancer epigenetics to provide an overview of epigenetic alterations induced by nutrition and environmental exposure. The majority of evidence suggests that various sources of excess estrogen correlate to future breast cancer development. In addition, maternal macro- and micronutrient balance appear to play a role in genomic regulation, and preliminary data suggest that specific superfoods, such as blueberries, have a protective epigenetic effect. Identifying the influence of environmental toxicants, hormonal exposure, maternal nutrition, and maternal disease on fetal epigenetics may have potential for development of new therapeutic approaches for the prevention of breast cancer.


Yiallourou AI, Ekonomou E, Tsamadias V, et al.
Association of FokI and PvuII polymorphisms with breast cancer staging and survival among Caucasian women: a prospective study.
J BUON. 2014 Jul-Sep; 19(3):633-42 [PubMed] Related Publications
PURPOSE: Both vitamin D and estrogens play an important role in breast cell growth and differentiation. Therefore, we hypothesized that FokI polymorphism in the Vitamin D Receptor (VDR) gene, as well as PvuII polymorphism in the Estrogen Receptor (ESR) gene might be associated with progression of breast cancer. The aim of this study was to prospectively examine the association of these polymorphisms with histopathological features and prognosis among women with histologically proven breast cancer.
METHODS: Patient characteristics, tumor histopathology, and genotyping of one VDR polymorphism variant (FokI) and one ER polymorphism variant (PvuII) were recorded. Patients were also routinely followed up.
RESULTS: There was a significant difference regarding nodal stage (p<0.001) between the different genotypes of FokI polymorphisms (FF, Ff, ff), even though a trend was also detected in the frequency between ductal and lobular type, as well as tumor size (p=0.077). When further analysis was performed regarding patients whose polymorphism included the f allele, we found statistically significant differences in tumor size (p<0.001), nodal stage (p=0.03), tumor grade (p=0.04) and lymphovascular invasion (p<0.001), while no differences in nodal status, distant metastases and tumor stage were noticed. No significant associations were found between any of the PvuII polymorphism variants and tumor histopathology and stage. No statistical significance was proven between FokI polymorphism's variants or f allele and overall or progression-free survival. Statistically significant associations between overall and progression- free survival and PvuII polymorphism's variants was demonstrated (p<0.001).
CONCLUSION: The f allele was associated with the presence of lymphovascular invasion and poorly differentiated tumors, whereas the PP genotype was associated with increased overall and progression-free survival, suggesting that this variant is related to a more favorable prognosis.

Related: Polymorphisms


Kalinsky K, Lim EA, Andreopoulou E, et al.
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.
Cancer Invest. 2014; 32(9):439-44 [PubMed] Related Publications
Hispanic women have higher breast cancer mortality compared to non-Hispanic whites. We evaluated for Proliferation Axis Score differences, as determined by Oncotype Dx, in Hispanic and non-Hispanic white women with newly diagnosed breast cancer. We matched 219 women, based upon age, stage, and nodal status. Compared to non-Hispanic whites, Hispanic women with hormone-sensitive, HER2-negative early-stage breast cancer had a higher Proliferation Axis Score. No differences were seen in Recurrence Score, ER, PR, or HER2 by Oncotype DX. CCNB1 and AURKA were significantly higher in Hispanic women. These tumor differences may help explain breast cancer outcome differences between the two ethnicities.

Related: MKI67 BIRC5 MYBL2 v-myb avian myeloblastosis viral oncogene homolog-like 2


Kasiappan R, Sun Y, Lungchukiet P, et al.
Vitamin D suppresses leptin stimulation of cancer growth through microRNA.
Cancer Res. 2014; 74(21):6194-204 [PubMed] Article available free on PMC after 01/11/2015 Related Publications
Obesity is a pandemic and major risk factor for cancers. The reduction of obesity would have been an effective strategy for cancer prevention, but the reality is that worldwide obesity has kept increasing for decades, remaining a major avoidable cancer risk secondary only to smoke. The present studies suggest that vitamin D may be an effective agent to reduce obesity-associated cancer risks in women. Molecular analyses showed that leptin increased human telomerase reverse transcriptase (hTERT) mRNA expression and cell growth through estrogen receptor-α (ERα) activation in ovarian cancer cells, which was suppressed by 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3]. The suppression was compromised when miR-498 induction by the hormone was depleted with microRNA (miRNA) sponges. In mice, high-fat diet (HFD) stimulation of ovarian tumor growth was remarkably suppressed by 1,25(OH)2D3 analogue EB1089, which was also compromised by miR-498 sponges. EB1089 did not alter HFD-induced increase in serum leptin levels but increased miR-498 and decreased the diet-induced hTERT expression in tumors. Quantitative RT-PCR analyses revealed an inverse correlation between hTERT mRNA and miR-498 in response to 1,25(OH)2D3 in estrogen-sensitive ovarian, endometrial, and breast cancers. The studies suggest that miR-498-mediated hTERT downregulation is a key event mediating the anti-leptin activity of 1,25(OH)2D3 in estrogen-sensitive tumors in women.

Related: MicroRNAs Ovarian Cancer ESR1 TERT


Bai F, Chan HL, Scott A, et al.
BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Cancer Res. 2014; 74(21):6161-72 [PubMed] Related Publications
BRCA1 mutation carriers are predisposed to developing basal-like breast cancers with high metastasis and poor prognosis. Yet, how BRCA1 suppresses formation of basal-like breast cancers is still obscure. Deletion of p18(Ink4c) (p18), an inhibitor of CDK4 and CDK6, functionally inactivates the RB pathway, stimulates mammary luminal stem cell (LSC) proliferation, and leads to spontaneous luminal tumor development. Alternately, germline mutation of Brca1 shifts the fate of luminal cells to cause luminal-to-basal mammary tumor transformation. Here, we report that disrupting Brca1 by either germline or epithelium-specific mutation in p18-deficient mice activates epithelial-to-mesenchymal transition (EMT) and induces dedifferentiation of LSCs, which associate closely with expansion of basal and cancer stem cells and formation of basal-like tumors. Mechanistically, BRCA1 bound to the TWIST promoter, suppressing its activity and inhibiting EMT in mammary tumor cells. In human luminal cancer cells, BRCA1 silencing was sufficient to activate TWIST and EMT and increase tumor formation. In parallel, TWIST expression and EMT features correlated inversely with BRCA1 expression in human breast cancers. Together, our findings showed that BRCA1 suppressed TWIST and EMT, inhibited LSC dedifferentiation, and repressed expansion of basal stem cells and basal-like tumors. Thus, our work offers the first genetic evidence that Brca1 directly suppresses EMT and LSC dedifferentiation during breast tumorigenesis.


Poremba C, Uhlendorff J, Pfitzner BM, et al.
Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.
Virchows Arch. 2014; 465(4):409-17 [PubMed] Article available free on PMC after 01/11/2015 Related Publications
Prognostic multigene expression assays have become widely available to provide additional information to standard clinical parameters and to support clinicians in treatment decisions. In this study, we analyzed the impact of variations in tissue handling on the diagnostic EndoPredict test results. EndoPredict is a quantitative reverse transcription PCR assay conducted on RNA from formalin-fixed, paraffin-embedded (FFPE) tissue that predicts the likelihood of distant recurrence in patients with ER-positive/HER2-negative breast cancer. In this study, we performed a total of 138 EndoPredict assays to study the effects of preanalytical variables such as time to fixation, fixation time, tumor cell content, and section storage time on the EndoPredict test results. A time to fixation of up to 12 h and fixation of up to 5 days did not affect the results of the gene expression test. Paired samples of FFPE sections with tumor cell content ranging from 15 to 95 % and tumor-enriched samples showed a correlation coefficient of 0.97. Test results of tissue sections that have been stored for 12 months at +4 or +20 °C showed a correlation of 0.99 when compared to results of nonstored sections. In conclusion, preanalytical tissue handling is not a critical factor for diagnostic gene expression analysis with the EndoPredict assay. The test can therefore be easily integrated into the standard workflow of molecular pathology.


Hagrass HA, Pasha HF, Ali AM
Estrogen receptor alpha (ERα) promoter methylation status in tumor and serum DNA in Egyptian breast cancer patients.
Gene. 2014; 552(1):81-6 [PubMed] Related Publications
BACKGROUND: Status of DNA methylation is one of the most common molecular alterations in human neoplasia. Because it is possible to detect these epigenetic alterations in the bloodstream of patients, we investigated the aberrant DNA methylation status of estrogen receptor alpha (ERα) in patient pretherapeutic sera and tissue.
MATERIALS AND METHODS: In this case control study the patient series consisted of 120 sporadic primary breast cancer cases and 100 patients with benign breast lesion. ER3, ER4, and ER5 primers were used for methylation-specific polymerase chain reaction (MSP) to analyze the CpG methylation of promoter region of ERα gene. Correlation between ER3, ER4, and ER5 methylation and clinicopathological characteristics of the patients was investigated.
RESULT: The methylation status of ER3, ER4 and ER5 was 65%, 26.7% and 61.7% in tissue respectively and 57.5%, 21.7% and 55.8% in serum respectively. The concordance between tumor and serum DNA methylation was 80%, 72% and 92% for ER3, ER4 and ER5 respectively.
CONCLUSIONS: This study demonstrated the potential utility of serum DNA methylation of ERα gene promoter as a non-invasive diagnostic and/or prognostic marker in patients with breast cancer.

Related: ESR1


Alli E, Solow-Cordero D, Casey SC, Ford JM
Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.
Cancer Res. 2014; 74(21):6205-15 [PubMed] Related Publications
Cancers due to germline mutations in the BRCA1 gene tend to lack targets for approved chemoprevention agents. This study aimed at a targeted chemoprevention strategy for BRCA1-associated malignancies. Mutant BRCA1 limits the base-excision DNA repair activity that addresses oxidative DNA damage, the accumulation of which heightens one's risk for cancer. Therefore, we conducted a high-throughput chemical screen to identify drug candidates that could attenuate the inhibitory effects of mutant BRCA1 on this repair activity, thereby describing a new class of DNA repair-activating chemopreventive agents. In the screen design, such drugs functioned by enhancing base-excision DNA repair of oxidative DNA damage in the presence of mutant BRCA1, with minimal cytotoxicity. We identified at least one new agent that decreased malignant properties associated with tumorigenesis, including anchorage-independent growth and tumor progression. This work offers a preclinical proof-of-concept for a wholly new approach to chemoprevention in carriers of BRCA1 mutations as a strategy to reduce the prevalence of BRCA1-associated malignancy.


Sheshadri N, Catanzaro JM, Bott AJ, et al.
SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling.
Cancer Res. 2014; 74(21):6318-29 [PubMed] Article available free on PMC after 01/11/2015 Related Publications
The serine/cysteine protease inhibitor SCCA1 (SERPINB3) is upregulated in many advanced cancers with poor prognosis, but there is limited information about whether it makes functional contributions to malignancy. Here, we show that SCCA1 expression promoted oncogenic transformation and epithelial-mesenchymal transition (EMT) in mammary epithelial cells, and that SCCA1 silencing in breast cancer cells halted their proliferation. SCCA1 overexpression in neu(+) mammary tumors increased the unfolded protein response (UPR), IL6 expression, and inflammatory phenotypes. Mechanistically, SCCA1 induced a prolonged nonlethal increase in the UPR that was sufficient to activate NF-κB and expression of the protumorigenic cytokine IL6. Overall, our findings established that SCCA1 contributes to tumorigenesis by promoting EMT and a UPR-dependent induction of NF-κB and IL6 autocrine signaling that promotes a protumorigenic inflammation.

Related: Signal Transduction IL6


Bae E, Sato M, Kim RJ, et al.
Definition of smad3 phosphorylation events that affect malignant and metastatic behaviors in breast cancer cells.
Cancer Res. 2014; 74(21):6139-49 [PubMed] Related Publications
Smad3, a major intracellular mediator of TGFβ signaling, functions as both a positive and negative regulator in carcinogenesis. In response to TGFβ, the TGFβ receptor phosphorylates serine residues at the Smad3 C-tail. Cancer cells often contain high levels of the MAPK and CDK activities, which can lead to the Smad3 linker region becoming highly phosphorylated. Here, we report, for the first time, that mutation of the Smad3 linker phosphorylation sites markedly inhibited primary tumor growth, but significantly increased lung metastasis of breast cancer cell lines. In contrast, mutation of the Smad3 C-tail phosphorylation sites had the opposite effect. We show that mutation of the Smad3 linker phosphorylation sites greatly intensifies all TGFβ-induced responses, including growth arrest, apoptosis, reduction in the size of putative cancer stem cell population, epithelial-mesenchymal transition, and invasive activity. Moreover, all TGFβ responses were completely lost on mutation of the Smad3 C-tail phosphorylation sites. Our results demonstrate a critical role of the counterbalance between the Smad3 C-tail and linker phosphorylation in tumorigenesis and metastasis. Our findings have important implications for therapeutic intervention of breast cancer.

Related: Signal Transduction SMAD3


Sasaki A, Tsunoda Y, Tsuji M, et al.
Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Anticancer Res. 2014; 34(9):4893-7 [PubMed] Related Publications
No targeted-therapy has been established for triple-negative breast cancer accompanied by mutations in breast cancer susceptibility gene1 (BRCA1) mutation. In the present study, using BRCA1 wild-type cells (MDA-MB-231) and BRCA1-mutated cells (MDA-MB-436), we investigated miRNA expression and apoptosis on day 1 after addition of gemcitabine-alone and in combination with poly ADP-ribose polymerase-1 (PARP1) inhibitor. After drug treatment, there were significantly fewer apoptotic BRCA1 wild-type cells than BRCA1-mutated cells. Expression of miRNA-26a, -29b, -100, and -148a increased in BRCA1 wild-type cells exposed to gemcitabine-alone and in combination with the PARP1 inhibitor. The addition of PARP1 inhibitor reduced miR-206 expression in BRCA1 wild-type cells but increased it in BRCA1-mutated cells. It was suggested that miR-206 serves as a target molecule of PARP1 inhibitor combination therapy for BRCA1 wild-type triple-negative breast cancer cells.

Related: Apoptosis MicroRNAs Gemcitabine


Loibl S, von Minckwitz G, Schneeweiss A, et al.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
J Clin Oncol. 2014; 32(29):3212-20 [PubMed] Related Publications
PURPOSE: Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in breast cancer, with mutations in PIK3CA being the most common. This study investigated the association between PIK3CA genotype and pathologic complete response (pCR) rates in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with either dual or single anti-HER2 treatment in addition to neoadjuvant chemotherapy.
PATIENTS AND METHODS: PIK3CA mutations in 504 tumor samples from participants in the neoadjuvant GeparQuattro, GeparQuinto, and GeparSixto studies were evaluated. All HER2-positive patients received either trastuzumab or lapatinib or the combination plus anthracycline-taxane chemotherapy. PIK3CA mutations were evaluated in formalin-fixed, paraffin-embedded tissues from core biopsies with a tumor cell content of ≥ 20% by using classical Sanger sequencing of exon 9 and exon 20.
RESULTS: Overall, 21.4% of the patients harbored a PIK3CA mutation. Detection of a PIK3CA mutation was significantly associated with a lower pCR rate (19.4% with PIK3CA mutation v 32.8% with PIK3CA wild-type; odds ratio [OR], 0.49; 95% CI, 0.29 to 0.83; P = .008). In the 291 hormone receptor (HR) -positive tumors, pCR rate was 11.3% with a PIK3CA mutation compared with 27.5% with PIK3CA wild-type (OR, 0.34; 95% CI, 0.15 to 0.78; P = .011). In 213 patients with HR-negative tumors, pCR rate was 30.4% with PIK3CA mutation and 40.1% without (OR, 0.65; 95% CI, 0.32 to 1.32; P = .233; interaction test P = .292). In multivariable analysis, HR status and PIK3CA status provided independent predictive information. In patients with PIK3CA mutation, the pCR rates were 16%, 24.3%, and 17.4% with lapatinib, trastuzumab, and the combination, respectively (P = .654) and in the wild-type group, they were 18.2%, 33.%, and 37.1%, respectively (P = .017). Disease-free survival and overall survival were not statistically significantly different between patients with mutant and wild-type PIK3CA.
CONCLUSION: HER2-positive breast carcinomas with a PIK3CA mutation are less likely to achieve a pCR after neoadjuvant anthracycline-taxane-based chemotherapy plus anti-HER2 treatment, even if a dual anti-HER2 treatment is given.

Related: Lapatinib (Tyverb) Trastuzumab (Herceptin)


Sherman ME, Piedmonte M, Mai PL, et al.
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
J Clin Oncol. 2014; 32(29):3275-83 [PubMed] Article available free on PMC after 10/10/2015 Related Publications
PURPOSE: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study.
PARTICIPANTS AND METHODS: This analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participant's mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression.
RESULTS: Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P < .001). In multivariable models, positive BRCA1/2 mutation status (P = .0056), postmenopausal status (P = .0023), and abnormal CA-125 levels and/or TVU examinations (P < .001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign.
CONCLUSION: Clinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO. BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.

Related: Fallopian Tube Cancer BRCA1 BRCA2 Cancer of Unknown Primary Ovarian Cancer


Wang QF, Ding H, Liu BR, Zhang K
[Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014; 43(4):427-33 [PubMed] Related Publications
OBJECTIVE: To generate two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer and to compare their biological properties.
METHODS: The genetically engineered mice previously developed with mouse mammary tumor virus (MMTV) promoter driven expression of activated ErbB2/Neu and recombinant Cre (FVB/N-MMTV-NIC) were interbred with Flox-PTEN mice; and FVB/N-ErbB2KI mice, harboring endogenous promoter driven activated ErbB2/Neu expression, FVB/N-MMTV-Cre mice and the flox-PTEN mice were interbred. Neu, Cre and PTEN genes were amplified by PCR for genotyping of the offsprings. ErbB2/Neu and PTEN expression in mammary tumors were detected by immunohistochemistry. Tumor formation time, tumor number, histopathology and lung metastasis were compared between two models, Ki-67 expression was detected by immunohistochemistry, and TUNEL staining of tumor tissues was performed.
RESULTS: Two genetically engineered mouse models of ErbB2/Neu positive-PTEN homozygous deficient breast cancer were generated. The models were confirmed by genotyping and immunohistochemistry. One model with exogenous MMTV promoter driven expression of activated ErbB2/Neu and Cre coupling PTEN disruption was designated as NIC/PTEN(-/-) mice, and the other with MMTV-Cre induced endogenous promoter driven expression of activated ErbB2/Neu with PTEN disruption was designated as ErbB2KI/PTEN(-/-) mice. The tumor formation time in NIC/PTEN(-/-) mice was significantly shorter than that of ErbB2KI/PTEN(-/-) mice (30 vs 368 d, P<0.01); the number of tumor and incidence of lung metastasis was also significantly higher in NIC/PTEN(-/-) mice (10 vs 1-2 and 75.0% vs 37.5%, respectively, Ps<0.01). The Two models displayed distinct histopathological morphology. NIC/PTEN(-/-) tumor showed more Ki-67 positive cells than ErbB2KI/PTEN(-/-) tumor did (86.9%±2.8% vs 37.4%±7.2%, P<0.01), while the amount of cell apoptosis in tumors was not significantly different between two models.
CONCLUSION: Two genetically engineered mouse models of ErbB2/Neu positive-PTEN homozygous deficient breast cancer with different phenotypes have been successfully generated, which may provide useful resource for further investigation of the initiation and progression of HER2/ErbB2 breast cancer, as well as for the development of novel prevention and treatment regimens of this malignance.

Related: PTEN


Fabris VT
From chromosomal abnormalities to the identification of target genes in mouse models of breast cancer.
Cancer Genet. 2014; 207(6):233-46 [PubMed] Related Publications
Cytogenetic studies of breast cancer cells have identified numerous chromosomal imbalances, including gains in human chromosome regions 1q, 4p, 8q, and 20q and losses in regions 1p, 3p, 6q, 11q, 16q, 17p, and 22q. Mouse models have been developed to study the mechanisms of mammary carcinogenesis, and in most cases, the corresponding karyotypes have been reported. Here, I summarize the cytogenetic findings and the candidate genes that are involved in mammary tumorigenesis. The most commonly altered chromosomes in mouse breast cancer models are chromosomes 4 and 11, which are orthologous to human chromosomes that are also affected by chromosomal abnormalities in human breast cancer. The genes that are affected by chromosomal imbalances in mouse models have also been found to participate in human breast cancer. In addition, the amplification and overexpression of several new genes in mouse models have subsequently been confirmed in human breast cancer. In this review, I compile information on the available karyotypes for mouse breast cancer models.

Related: Cancer Cytogenetics


Tran HD, Luitel K, Kim M, et al.
Transient SNAIL1 expression is necessary for metastatic competence in breast cancer.
Cancer Res. 2014; 74(21):6330-40 [PubMed] Related Publications
SNAIL1 has been suggested to regulate breast cancer metastasis based on analyses of human breast tumor transcriptomes and experiments using cancer cell lines and xenografts. However, in vivo genetic experimental support for a role for SNAIL1 in breast cancer metastasis that develops in an immunocompetent tumor microenvironment has not been determined. To address this question, we created a genetic SNAIL1 model by coupling an endogenous SNAIL1 reporter with an inducible SNAIL1 transgene. Using multiple genetic models of breast cancer, we demonstrated that endogenous SNAIL1 expression was restricted to primary tumors that ultimately disseminate. SNAIL1 gene deletion either during the premalignant phase or after primary tumors have reached a palpable size blunted metastasis, indicating that late metastasis was the main driver of metastasis and that this was dependent on SNAIL1. Importantly, SNAIL1 expression during breast cancer metastasis was transient and forced transient, but not continuous. SNAIL1 expression in breast tumors was sufficient to increase metastasis.

Related: Signal Transduction


Li Y, Li W, Ying Z, et al.
Metastatic heterogeneity of breast cancer cells is associated with expression of a heterogeneous TGFβ-activating miR424-503 gene cluster.
Cancer Res. 2014; 74(21):6107-18 [PubMed] Related Publications
TGFβ signaling is known to drive metastasis in human cancer. Under physiologic conditions, the level of TGFβ activity is tightly controlled by a regulatory network involving multiple negative regulators. At metastasis, however, these inhibitory mechanisms are usually overridden so that oncogenic TGFβ signaling can be overactivated and sustained. To better understand how the TGFβ inhibitors are suppressed in metastatic breast cancer cells, we compared miRNA expression profiles between breast cancers with or without metastasis and found that the miR424-503 cluster was markedly overexpressed in metastatic breast cancer. Mechanistic studies revealed that miR424 and miR503 simultaneously suppressed Smad7 and Smurf2, two key inhibitory factors of TGFβ signaling, leading to enhanced TGFβ signaling and metastatic capability of breast cancer cells. Moreover, antagonizing miR424-503 in breast cancer cells suppressed metastasis in vivo and increased overall host survival. Interestingly, our study also found that heterogeneous expression of the miR424-503 cluster contributed to the heterogeneity of TGFβ activity levels in, and metastatic potential of, breast cancer cell subsets. Overall, our findings demonstrate a novel mechanism, mediated by elevated expression of the miR424-503 cluster, underlying TGFβ activation and metastasis of human breast cancer.

Related: MicroRNAs SMAD7


Payne AW, Pant DK, Pan TC, Chodosh LA
Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.
Cancer Res. 2014; 74(21):6352-63 [PubMed] Article available free on PMC after 01/11/2015 Related Publications
Recurrent breast cancer is typically an incurable disease and, as such, is disproportionately responsible for deaths from this disease. Recurrent breast cancers arise from the pool of disseminated tumor cells (DTC) that survive adjuvant or neoadjuvant therapy, and patients with detectable DTCs following therapy are at substantially increased risk for recurrence. Consequently, the identification of pathways that contribute to the survival of breast cancer cells following therapy could aid in the development of more effective therapies that decrease the burden of residual disease and thereby reduce the risk of breast cancer recurrence. We now report that ceramide kinase (Cerk) is required for mammary tumor recurrence following HER2/neu pathway inhibition and is spontaneously upregulated during tumor recurrence in multiple genetically engineered mouse models for breast cancer. We find that Cerk is rapidly upregulated in tumor cells following HER2/neu downregulation or treatment with Adriamycin and that Cerk is required for tumor cell survival following HER2/neu downregulation. Consistent with our observations in mouse models, analysis of gene expression profiles from more than 2,200 patients revealed that elevated CERK expression is associated with an increased risk of recurrence in women with breast cancer. In addition, although CERK expression is associated with aggressive subtypes of breast cancer, including those that are estrogen receptor-negative, HER2(+), basal-like, or high grade, its association with poor clinical outcome is independent of these clinicopathologic variables. Together, our findings identify a functional role for Cerk in breast cancer recurrence and suggest the clinical utility of agents targeted against this prosurvival pathway.


He DX, Gu XT, Jiang L, et al.
A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.
Mol Pharmacol. 2014; 86(5):536-47 [PubMed] Related Publications
We previously demonstrated that the overexpression of transient receptor potential channel C5 (TRPC5) and nuclear factor of activated T-cells isoform c3 (NFATC3) are essential for cancer chemoresistance, but how TRPC5 and NFATC3 are regulated was still unclear. In this study, microRNA 320a (miR-320a) was found to be down-regulated in chemoresistant cancer cells. MiR-320a directly targeted TRPC5 and NFATC3, and down-regulation of miR-320a triggered TRPC5 and NFATC3 overexpression. In chemoresistant cells, down-regulation of miR-320a was associated with regulation by methylation, which implicated promoter methylation of the miR-320a coding sequence. Furthermore, the transcription factor v-ets erythroblastosis virus E26 oncogene homolog 1 (ETS-1), which inhibited miR-320a expression, was activated in chemoresistant cancer cells; such activation was associated with hypomethylation of the ETS-1 promoter. Lastly, the down-regulation of miR-320a and high expression of TRPC5, NFATC3, and ETS-1 were verified in clinically chemoresistant samples. Low expression of MiR-320a was also found to be a significant unfavorable predictor for clinic outcome. In conclusion, miR-320a is a mediator of chemoresistance by targeting TRPC5 and NFATC3. Expression of miR-320a is regulated by methylation of its promoter and that of ETS-1.

Related: MicroRNAs


Otani Y, Miyake T, Kagara N, et al.
BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.
Cancer Sci. 2014; 105(10):1369-76 [PubMed] Related Publications
The breast cancer susceptibility gene 1 (BRCA1) and glutathione S-transferase P1 (GSTP1) promoters are reportedly often methylated in breast cancer tissues. Their methylation status in surrounding normal breast tissues has not been examined thoroughly although this may well be important for a better understanding of breast carcinogenesis. In this study, BRCA1 and GSTP1 promoter methylation was examined by methylation-specific PCR assay. Patients with BRCA1-methylated (n = 15) or BRCA1-unmethylated (n = 15) tumors and those with GSTP1-methylated (n = 9) or GSTP1-unmethylated (n = 11) tumors were included in the present study. Methylation status of manually micro-dissected normal epithelial cells from the formalin-fixed paraffin-embedded sections of normal breast tissues adjacent to and distant from the tumors was examined at multiple sites (n = 1-5). Of the 15 patients with BRCA1-methylated tumors, 9 harbored BRCA1 promoter methylation in at least one site of the normal breast tissues. However, no BRCA1 promoter methylation was observed at any site of the normal tissues of the 15 patients with BRCA1-unmethylated tumors. No GSTP1 promoter methylation was observed in the normal tissues regardless of the methylation status of the tumors. The presence of BRCA1 promoter methylation in the normal tissues was confirmed in the epithelial cells enriched with the magnetic-activated cell sorting method. Our findings suggest that a small proportion of normal breast epithelial cells with BRCA1 promoter methylation can be precursor cells from which BRCA1-methylated breast tumors may originate. This does not apply to GSTP1 promoter methylation.

Related: GSTP1


Gatza ML, Silva GO, Parker JS, et al.
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.
Nat Genet. 2014; 46(10):1051-9 [PubMed] Related Publications
Elucidating the molecular drivers of human breast cancers requires a strategy that is capable of integrating multiple forms of data and an ability to interpret the functional consequences of a given genetic aberration. Here we present an integrated genomic strategy based on the use of gene expression signatures of oncogenic pathway activity (n = 52) as a framework to analyze DNA copy number alterations in combination with data from a genome-wide RNA-mediated interference screen. We identify specific DNA amplifications and essential genes within these amplicons representing key genetic drivers, including known and new regulators of oncogenesis. The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective. This general strategy has the potential to identify therapeutic targets within amplicons through an integrated use of genomic data sets.

Related: Signal Transduction


Tell RW, Horvath CM
Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.
Proc Natl Acad Sci U S A. 2014; 111(35):12787-92 [PubMed] Article available free on PMC after 02/03/2015 Related Publications
Signal transducer and activator of transcription 3 (STAT3), a latent transcription factor associated with inflammatory signaling and innate and adaptive immune responses, is known to be aberrantly activated in a wide variety of cancers. In vitro analysis of STAT3 in human cancer cell lines has elucidated a number of specific targets associated with poor prognosis in breast cancer. However, to date, no comparison of cancer subtype and gene expression associated with STAT3 signaling in human patients has been reported. In silico analysis of human breast cancer microarray and reverse-phase protein array data was performed to identify expression patterns associated with STAT3 in basal-like and luminal breast cancers. Results indicate clearly identifiable STAT3-regulated signatures common to basal-like breast cancers but not to luminal A or luminal B cancers. Furthermore, these differentially expressed genes are associated with immune signaling and inflammation, a known phenotype of basal-like cancers. These findings demonstrate a distinct role for STAT3 signaling in basal breast cancers, and underscore the importance of considering subtype-specific molecular pathways that contribute to tissue-specific cancers.

Related: MicroRNAs STAT3


Prat A, Carey LA, Adamo B, et al.
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
J Natl Cancer Inst. 2014; 106(8) [PubMed] Article available free on PMC after 02/03/2015 Related Publications
BACKGROUND: The clinical impact of the biological heterogeneity within HER2-positive (HER2+) breast cancer is not fully understood. Here, we evaluated the molecular features and survival outcomes of the intrinsic subtypes within HER2+ breast cancer.
METHODS: We interrogated The Cancer Genome Atlas (n = 495) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) datasets (n = 1730) of primary breast cancers for molecular data derived from DNA, RNA and protein, and determined intrinsic subtype. Clinical HER2 status was defined according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines or DNA copy-number aberration by single nucleotide polymorphism arrays. Cox models tested the prognostic significance of each variable in patients not treated with trastuzumab (n = 1711).
RESULTS: Compared with clinically HER2 (cHER2)-negative breast cancer, cHER2+ breast cancer had a higher frequency of the HER2-enriched (HER2E) subtype (47.0% vs 7.1%) and a lower frequency of Luminal A (10.7% vs 39.0%) and Basal-like (14.1% vs 23.4%) subtypes. The likelihood of cHER2-positivity in HER2E, Luminal B, Basal-like and Luminal A subtypes was 64.6%, 20.0%, 14.4% and 7.3%, respectively. Within each subtype, only 0.3% to 3.9% of genes were found differentially expressed between cHER2+ and cHER2-negative tumors. Within cHER2+ tumors, HER2 gene and protein expression was statistically significantly higher in the HER2E and Basal-like subtypes than either luminal subtype. Neither cHER2 status nor the new 10-subtype copy number-based classification system (IntClust) added independent prognostic value to intrinsic subtype.
CONCLUSIONS: When the intrinsic subtypes are taken into account, cHER2-positivity does not translate into large changes in the expression of downstream signaling pathways, nor does it affect patient survival in the absence of HER2 targeting.

Related: Signal Transduction


Moirangthem DS, Laishram S, Borah JC, et al.
Cephalotaxus griffithii Hook.f. needle extract induces cell cycle arrest, apoptosis and suppression of hTERT and hTR expression on human breast cancer cells.
BMC Complement Altern Med. 2014; 14:305 [PubMed] Article available free on PMC after 02/03/2015 Related Publications
BACKGROUND: Cephalotaxus spp. are known to possess anticancer potential. In this present work, for the first time the effects of C. griffithii needle (CGN) extracts on human cancer cells were examined.
METHODS: The CGN was successively extracted with petroleum ether (PE), acetone and methanol. The extracts were tested for its effect on proliferation of cancer cells (MTT assay on HeLa, ZR751 and HepG2). Extract that showed the maximum growth inhibitory effect was subjected for mechanism of action study. These included apoptosis (morphological and DNA fragmentation assay), cell cycle (flow cytometry), caspase expression (Western blot) and activity (assay kit), p53 (western blot and TP53 siRNA interference) and telomerase expression (reverse transcriptase PCR) analysis.
RESULTS: Among the extracts, PE extract induced maximum cytotoxicity, with highest death occurred in ZR751 cells. Since, PE extract induced cell death was highest among the CGN extracts, with maximum cancer cell death occurred in ZR751 cells; we carried out mechanism study of PE extract induced ZR751 cell death. It was observed that PE extract induced ZR751 cell death was associated with cell cycle arrest and apoptosis by activating both intrinsic and extrinsic apoptotic pathways. Knock down study revealed that p53 is essential for loss of ZR751 cell viability induced by PE extract. Further, PE extract down-regulated hTERT, hTR, and c-Myc expression. Thin layer chromatography analysis indicated the presence of unique phytochemicals in PE extract.
CONCLUSION: Based on the observations, we concluded that PE extract of C. griffithii needle contains important phyto-components with multiple cellular targets for control of breast cancer and is worthy of future studies.

Related: Apoptosis TERC TERT


Zhu X, Dent S, Paquet L, et al.
Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Eur J Cancer. 2014; 50(15):2544-9 [PubMed] Related Publications
BACKGROUND: Oncotype DX recurrence score is a multi-gene assay which quantifies the risk of distant recurrence in patients with hormone receptor-positive (HR+) early breast cancer (EBC) treated with tamoxifen, and predicts the magnitude of clinical benefit of adjuvant chemotherapy. This retrospective study examined factors that were associated with use of Oncotype DX assay at a tertiary care cancer centre in Ottawa, Canada.
METHODS: One hundred consecutive patients (pts) diagnosed with HR+, HER2/neu negative EBC (stage I-II), who underwent Oncotype DX testing (Test Group) between 1st April 2010, and 30th June 2011 were included in the study. A second cohort of 100 randomly selected patients with HR+, HER2/neu negative EBC diagnosed from the same time period who did not receive Oncotype DX testing were used as the control group (Control Group). Demographic and clinicopathologic data were obtained from review of charts. Logistic regression was performed to identify variables associated with Oncotype DX usage.
FINDINGS: Median age was 58 years (r: 26-77) in Test Group and 63 years (r: 30-81) in Control Group. Sixty-two patients in the Test Group had T1 tumours, compared with 71 in the Control Group. The median 10-year recurrence risks from Adjuvant! Online were 19% and 12% in the Test Group and Control Group, respectively. Factors significantly associated with the utilisation of Oncotype DX assay on multivariate analysis include age 50-64 (p=0.049), tumour size 10.1-20mm (p=0.008) and grade 2 histological grade (p=0.004).
INTERPRETATION: Usage of Oncotype DX assay is associated with several clinicopathological factors. These factors reflect the clinical uncertainty of benefit from chemotherapy in these subpopulations of patients and suggest how Oncotype DX assay could complement clinicopathological factors in helping clinicians on treatment selection.


Contents

Found this page useful?

Disclaimer: This site is for educational purposes only; it can not be used in diagnosis or treatment.

Cite this page: Cotterill SJ. Breast Cancer, Cancer Genetics Web: http://www.cancerindex.org/geneweb/X0401.htm Accessed: date

Creative Commons License
This page in Cancer Genetics Web by Simon Cotterill is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Note: content of abstracts copyright of respective publishers - seek permission where appropriate.

 [Home]    Page last revised: 14 January, 2015     Cancer Genetics Web, Established 1999